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Foreword
Erasmus MC’s position in the world
Research is a global enterprise. Within the scientific discourse, 
innovative ideas are conceived, developed, verified, and applied. 
This is why Erasmus MC can only exist as a research institute 
if it is part of an international platform. Fortunately, we have 
achieved a respectable international reputation. The influential 
Times Higher Education Ranking ranks Erasmus MC’s clinical 
research within the world’s top 20, together with prestigious 
institutes, such as Harvard, Johns Hopkins, Oxford, Cambridge 
and Karolinska Institute.
But patient care and medical education -  both core tasks of 
Erasmus MC in addition to research - are also becoming 
increasingly international. We encourage our medical students 
to spend at least a few months abroad during their study to get 
a feel for international collaboration and cultural differences. 
Furthermore,  we also see an increasing number of foreign 
patients choosing to be treated in our hospital. This could 
very well be the result of our strong international reputation in 
research.
While research has always been international, I think we are 
only at the beginning of the internationalization of patient care. 
Modern means of information exchange, communication, and 
transport have made the world smaller. Patients, organizations, 
and governments will increasingly behave like consumers trying 
to find  the best quality at the best price. 
Erasmus MC has to ensure that it not only delivers the best 
quality, but that this is also recognized by audiences across the 
world. ‘Be good and let others know’. Our excellent scientific 
reputation, based on solid numbers, is a great starting point for 
internationalization in general.
Erasmus Journal of Medicine not only provides medical students 
of Erasmus MC with a platform to take their first steps into the 
world of scientific publishing, but it also prepares them for a 
future in the global world of both medical science and practice.
Prof. Dr. Jaap Verweij, Dean and vice-chairman of the Executive 
Board of Erasmus MC
Dr. Ajda Rowshani, Co-editor in chief and chair of the editorial 
board
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Editorial comment
The board of Erasmus Journal of Medicine (EJM) consists of a 
dynamic teamwork between students and staff members. Since 
the Erasmus University Medical Center (Erasmus MC) serves 
as a matrix for aspiring as well as successful academics, we 
are continuously receiving scientific articles for review.With 
the same aim in mind – providing students and researchers of 
the Medical Faculty of the Erasmus University an approachable 
way to publish scientific articles and to promote research 
as early as possible - we strive to push the boundaries of this 
Journal  towards an acknowledgeable faculty journal.  Starting 
with a bustling period of managing a pile of articles, the end 
result of browsing through a brand new issue always feels quite 
satisfying! 
As an annual event, the best EJM article receives an award 
which is personally handed over by our Dean. This year, the 
award ceremony took place during ‘In Praise of Medicine’ 
in October. After extensive evaluationby our scientific jury, 
an orthopaedics and radiology related article by Stephanie de 
Graaff et al. was chosen as the best among all. They studied the 
association between knee joint shape and osteoarthritis. This 
research article, 
our way to an acknowledgeable 
journal: a journey with research, 
teamwork and winners
‘The association between knee joint shape and osteoarthritis 
development in middle-aged, overweight and obese women’, 
can be found in the second issue of vol. 4, which is published 
in March 2015. A population with an important worldwide 
health problem, i.e. obesity, is selected in this study to 
investigate whether knee shapes can predict the incidence 
and the progression of knee osteoarthritis. The clinical relevanc 
of their research question is clear: the early detection of 
those distinctive knee shape characteristics associated with 
the high-risk of osteoarthritis . In an aging  population with an 
steadily growing incidence of obesity, early detection of this 
clinical problem is essential.
It remains a tough job to choose the best article of each year, 
meaning that the articles of Erasmus MC’s students are of high 
quality. This is also approved by external evaluation: PubMed 
reviewers noticed that especially our systematic reviews can be 
rated as excellent. Congratulations to all our student authors! 
Thank you for choosing EJM.
Student editors: Linda Al-Hassany, Mostafa Mohseni,
Begum Pekbay, Iris van der Sar 
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The Erasmus Journal of Medicine (EJM) is, to the best of 
our knowledge, a unique scientific journal. On one hand it is 
primarily meant for original articles written by medical 
students. On the other hand it has a complete reviewing 
system, including peer review, and editorial decisions. It therefore 
provides a unique training opportunity for medical students 
who have scientific aspirations.
The EJM is by origin first and foremost a student initiative, 
initiated by the Erasmus MC Studentenraad. In 2008 they 
actually got triggered by the launch of another biomedical 
journal at another Dutch university that was filled with 
student products. A small delegation, consisting of Christian von 
Kriegenbergh and Wu Wei, visited the offices of said journal 
and came to the conclusion that something more exciting and 
more professional should be possible within the Rotterdam 
context.
Indeed the conditions at Erasmus MC were optimal at the 
time. The medical bachelor had chosen to seek a profile that 
stressed the combination of medicine and science, fitting for the 
largest medical research institute in the Netherlands. Immediate 
support was found with Prof. Themmen, the coordinator of the 
BSc program. He had already been heavily involved in student 
profile tracks that had similar objectives, such as the Junior 
Med School and the Erasmus MC Honours Class. 
Possibly that strongest support came from the Dean of Erasmus 
MC. At the time this was Prof. Pols and he had,  coincidently, 
proposed a similar journal with a similar setup during his 
inaugural speech as full professor in 1998. During this speech, 
Prof. Pols had even proposed a name for such a journal: Eras-
mus Journal of Medicine. Thus it seemed only fitting to start a 
journal with that name, a decade after it had been proposed.
The first Head editor of EJM, Prof. Dippel, created a format 
that is still in use: both the editorial board and the reviewers of 
EJM would consist of equal amounts of students, established 
clinicians and scientists. This has been a formula that has been 
successful ever since.
Maarten Frens, and Wu Wei 
Department of Neuroscience, Erasmus MC; m.frens@erasmusmc.nl
 Department of Orthopedics, Erasmus MC; w.wei@erasmusmc.nl
Birth of a unique journal 
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Editorial comment
Many transplant programs have been implemented all over the 
world to increase the number of kidney donors, with varying 
successes, In this issue of Erasmus Journal of Medicine, de 
Graaff appealsfor financial compensation for kidney donation. 
A financial compensation could increase the number of living 
donations. She also refers to the potential negative effects of 
such a concept, like jeopardizing the equality principle. 
Paid kidney donation might target the weakest / poorest of 
society, since their decision to donate might be influenced 
by money. Therefore there might not be a free choice and so 
the informed consent would be invalid. However, if a person 
is capable of understandingthe risks associated with kidney 
donation, what is unethical about that person’s decision? One 
could argue that the person is motivated by ‘wrong’ reasons 
(money instead of altruism), but is that in itself a bad thing? In 
some countries donation of blood or stem cells is financially 
reimbursed and accepted. Moreover,financial incentives are 
often used to move people to accomplish a social goal The 
Hippocratic tradition (primum non nocere) and the 
Philosophical tradition (respect for human life) are used to 
criticize the paid living donor concept, because healthy 
individuals are then exposed to a higher and an unnecessary 
risk of complications and even death. However, this argument 
also implies for non-paid living donation. So the Hippocratic 
and Philosophical tradition add no extra ethical limitations, 
especially since one can assume that doctors will still do 
everything to minimize the risk for the donor.
However, before we implement this financial compensation, let 
us reflect on two other issues. First, paid donation could create 
a system of organ selling and organ trafficking. This creates 
an enormous fear for the care providers in the transplant 
community. An organ cannot be traded or offered to the highest 
bidder. The WHO states “Trade is inconsistent with the most 
basic human values and contravenes the Universal Declaration 
of Human Rights and the spirit of the WHO Constitution.” 
Moreover, such a ‘market’ profit could become more important 
than the quality of the transplantation care. To prevent organ 
selling and organ trafficking, a paid donation system should be 
strictly regulated by the government, and it should be subjected 
to the same allocation rules as it is the common practice 
nowadays. So the allocation should be transparent and fair. 
Second, prior to the implementation of such a paid donation 
principle , it seems necessary to consult the general public. 
Organ donation as a whole greatly depends on public view and 
acceptance. If the public views paid donation as unacceptable, 
the implementation could have detrimental effects for the 
current running programs, for example the willingness to donate 
after death resulting in a lower number of total organs donated.
 
Martijn W.F. van den Hoogen, MD , PhD
Erasmus MC, Department of Nephrology and 
Renal Transplantation
Kidney donation  
reimbursement; is it ethical?
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Editorial comment
Jochem Bosch et al. performed in this issue a literature review 
to find SNP variants associated with Testicular germ cell 
tumor (TGCT) development. These kind of tumors are worldwide 
the most common malignancy in men aged 15–45 years and 
accounts for approximately 1% of all cancers in males. 
Therefore, the relevance of research for this type of malignancy 
seems to be relatively high.
Early detection of tumors is a very hot topic in medicine, 
because early detection is associated with less intensive 
treatment and higher survival rates in many types of cancer. 
Bosch et al.  show that a few SNPs that are strongly 
associated with the development of TGCT. Based on this 
finding the authors recommend to screen al young men for 
the presence of these specific SNPs, for early detection and 
recommend follow up of these men to allow early detection of 
TGCT.
The current survival rate of patients treated for TGCT is 
already 95% without screening for SNPs. This is because of the 
remarkable sensitivity to radiotherapy and/or chemotherapy 
of these tumors. Nevertheless, this article recommends a 
(worldwide) screening for SNPs and a follow-up in those 
carrying these SNPs.
SNPs are associated with increased risk, but it will not be 
sure that a patient will develop cancer. And it’s not sure that 
survival will be much better, because survival is already really 
high. Also, a person with the specific SNP will maybe have 
psychological burden of knowing to have an increased risk for 
developing cancer. 
It would be interesting if the authors would have dwelled upon 
how many saved lives a screening program would yield and 
weighed the advantages and disadvantages of cancer screening 
in general and in particular with regard to TGCT.
Of course we can discuss about the weight of low cost 
effectiveness, because in the other hand, it will be absolutely 
great when we could reach a 100% survival of this tumor by 
just screening for a few SNPs. Or to screen the high-risk men 
is another option to be keep in mind, based on family history or 
other possible risk factors. 
It could be a step forward in medicine, but we must not forget 
the effort for an enormous logistical operation with high cost 
like this. 
On behalf of the editorial board of the EJM,
Ron de Bruin and Iris van der Sar
is screening always the best  
option?
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the role of positron-emission 
tomography in the diagnosis of 
giant cell arteritis  
A systematic review and meta-analysis
Niels van der Schafta, Kars Compagnea, Albert Groenendijka, Marijn Visb
a Medical student, Erasmus University Medical Center, Rotterdam, the Netherlands
b Supervisor, Department of Rheumatology, Erasmus University Medical Center, Rotterdam, the Netherlands
Correspondence: Niels van der Schaft, e-mail: 368021ns@student.eur.nl
abstract
Background: Giant cell arteritis (GCA) is an inflammatory disease of the larger vessels, typically affecting the temporal arteries, 
but involvement of the carotid and thoracic arteries is not uncommon. Serious complications such as blindness can occur if the 
disease is left untreated. Currently, the gold standard test for GCA is a temporal biopsy, but this invasive technique is not without 
risks and frequently inaccurate. We investigate the use of 18-fluoro-desoxyglucose (18F-FDG) positron emission tomography 
(PET) as a new diagnostic means in GCA.
Methods: We performed a literature search in the MEDLINE database for original research articles written in the English 
language that discussed the use of PET in diagnosing GCA. After applying selection criteria, 9 articles were included for literature 
review and 4 of these were incorporated in a meta-analysis.
Results: 18-FDG uptake in the extracranial arteries is correlated to the presence GCA within patients suspected for vasculitis. In 
our meta-analysis we found the following results: sensitivity 85% (95% CI; 74-92%, I2=0.0%), specificity 91% (95% CI; 82-96%, 
I2=31.2%), positive likelihood ratio 7.18 (95% CI; 3.43-15.06, I2 =10.1%) and negative likelihood ratio 0.19 (95% CI; 0.11-0.33, 
I2= 0.0%).
Discussion: 18F-FDG-PET cannot replace temporal artery biopsy at the present time, because of its limited ability to visualise the 
cranial arteries. However, PET may be provide valuable information when extracranial involvement is suspected, specifically in 
biopsy-negative patients who are strongly suspected of having GCA.
Systematic Review
Background
Giant cell arteritis (GCA) is one of the two types of large vessel 
vasculitis, as classified according to the 2012 Revised International 
Chapel Hill Consensus Conference.[1] GCA is the most common 
primary systemic vasculitis in adults and usually occurs in those 
over the age of 50 years. This age criterion distinguishes GCA 
from the other type of large vessel vasculitis, Takayasu’s arteritis, 
a disease phenotypically similar to GCA but most commonly 
occuring in those aged younger than 50 years.[1] 
Histopathologically, however, Takayasu’s arteritis and GCA are 
indistinguishable.[1] GCA typically affects the temporal arteries, 
but involvement of the aorta and its major branches, mainly the 
branches of the carotid and vertebral arteries, is often observed. 
With the increasing use of novel imaging techniques, large vessel 
involvement is more frequently recognized.[2,3]
GCA is the most common primary systemic vasculitis in adults. 
In Europe and North America, the estimated prevalence is 
200 per 100 000 and the incidence is 20–30 per 100 000.[4-8] 
If left undiagnosed, the disease progresses and can result in 
audiovestibular dysfunction, generalised peripheral polyneuro-
pathy, stroke, myocardial infarctions, and blindness.[9-12]
 The clinical presentation varies significantly between cases 
and diagnosing CGA can be difficult, but a variety of diagnostic 
tools are helpful in the diagnosis of GCA. These include 
haemoglobin counts, ESR/CRP, liver biochemistry and, most 
importantly, temporal artery biopsies. Because the latter test 
produces far more specific results than the former three [13], a 
positive temporal artery biopsy is currently regarded as the gold 
standard in the diagnosis of GCA.[14]
 However, this gold standard test is not without its limitations. 
In their 1983 study, Hall and colleagues [15] already found that 
its sensitivity is not ideal (85%). They also remarked that in other, 
similar studies, sensitivity had varied between 67% and 97%. In 
these studies, a diagnosis of GCA was made using other strong 
radiological, pathological or clinical evidence.[15,16] This 
means that the current gold standard test will still leave more than 
1 in every 10 patients undiagnosed. These results appear to hold 
true in more recent research, as a Spanish study [17] conducted 
in 2001 found that 29 of 190 patients with proven GCA had a 
negative initial temporal artery biopsy. 
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Biopsies might be negative because the biopsy missed the 
pathologically inflamed area, or because the GCA has an 
atypical phenotype and does not involve the temporal arteries.
[18] Such extracranial involvement can occur in up to 74% of 
GCA patients.[19]
 The current imperfect gold standard and the serious 
morbidity and mortality that are associated with GCA led us to 
investigate alternative methods of diagnosing the disease. One 
such method is the use of positron emission tomography with 
or without computed tomography (PET or PET-CT) to detect 
large vessel inflammation or extracranial involvement secondary 
to GCA. PET has shown promise in detecting extracranial 
involvement of GCA in previous research.[19-22] A PET scan 
is a non-invasive assessment technique compared to temporal 
artery biopsies. Hemorrhage and facial nerve injury have been 
reported as complications of the biopsy procedure.[23,24] In 
addition, several studies report that PET has proven useful in 
diagnosing patients with fever or inflammation of unknown 
origin [25-27] and patients with large vessel vasculitis.[28-30] 
Therefore, the objective of this review is to determine whether 
PET, with or without an added CT component, is a valuable 
addition to the current diagnostic work-up of GCA. 
Methods
Literature search
We performed a search in the MEDLINE database for articles 
written in the English language that addressed the use of 18-FDG 
PET in the diagnostic process of GCA, up to September 2014. 
The exact MeSH-query we used was the following: 
(“Giant Cell Arteritis/diagnosis”[Majr] OR “Giant Cell Arteritis/ 
radiography”[Majr] OR “Giant Cell Arteritis/radionuclide 
imaging”[Majr]) AND ((“Radionuclide Imaging”[majr]) OR 
(“Positron-Emission Tomography”[Mesh])OR (“Fluorode-
oxyglucose F18/diagnostic use”[Mesh])) AND (“humans”[MeSH 
Terms] AND English[lang]) NOT “Case Reports”[ptyp]
We excluded case reports in our search query, because these do not 
provide systematically conducted clinical research for analysis. 
Three authors screened the abstracts independently for eligibility. 
During this process, a further selection was made based on the 
exclusion of abstract-only articles, non-filtered case reports, 
editorials, comment- and response articles, reviews, and papers 
that did not discuss the use of 18-FDG-PET in the diagnostic 
process of GCA. Consensus was reached in case of disagreement 
between authors during the screening process. Full-text versions 
of the remaining articles were read and their references screened 
for other suitable articles. Papers thus found were included in 
our literature review. Additionally, those articles which provided 
Bayesian numerical data (e.g. numbers of true positives, true 
negatives, false positives and false negatives) relevant for assess-
ment of the diagnostic accuracy of PET for GCA were included 
in a meta-analysis. Papers providing such data in incomplete 
form were included only if backwards calculation of sensitivity 
and specificity were possible. Our last search was performed on 
October 3, 2014. The selection process is shown in figure 1. 
Statistical analysis
Where applicable, we recorded the number of true positives, 
true negatives, false positives and false negatives provided by 
the respective authors, as found by PET-scanning using clinical 
criteria or positive temporal artery biopsies as the gold standard. 
In case the authors provided only part of this data, we reversely 
calculated the remainder of the data manually using Bayesian 
mathematics. This data was subsequently pooled and an 
overall sensitivity and specificity were determined. Additionally, 
an overall negative likelihood ratio (NLR) and positive 
likelihood ratio (PLR) were calculated with a random effects 
model. Between-study heterogeneity was assessed by means of 
an I2-test. Calculations were carried out by MetaDiSc version 
4.1.[31]
results
Literature review
The primary literature search yielded 37 articles, 9 of which were 
selected for inclusion in our literature review after excluding 
non-suitable articles (figure 1). 
 Walter et al. [32] used a four-category visual grading to 
evaluate 18F-FDG-uptake in a total of 30 PET-scans in patients 
with clinically confirmed GCA or Takayasu’s arteritis. ESR 
(p=0.007) and CRP levels (p=0.005) in patients were found to 
be significantly positively correlated with the score these patients 
were assigned on a visual grading scale used for quantifying 
active inflammation, applied after PET-scanning. High ESR/
CRP levels were also associated with a higher sensitivity of the 
PET-scan for the presence of large-vessel vasculitis compared 
to non-elevated ESR/CRP values (up to a maximum of 96% 
sensitivity at a CRP level of 130). Data analysis showed an 
overall sensitivity of 60% and a specificity of 99.8%. Walter and 
colleagues conclude that high ESR or CRP levels increase the 
sensitivity of PET as a diagnostic tool.
37 articles identified  
through MEDLINE search
9 articles selected for 
inclusion in review
4 articles included in  
statistical analysis
28 articles excluded:
• abstracts
• non-filtered case reports
• editorials
• reviews
•  FDG-PET not used  
diagnostically
• article no longer available
5 articles excluded:
•  Diagnostic accuracy  
not assessed
•  GCA grouped with  
other vasculitides
Figure 1- Data selection procedure of literature review 
and statistical analysis
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Blockmans et al. [33] conducted a study to evaluate the use of 
18F-FDG-PET in GCA and polymyalgia rheumatica (PMR). In 
a cohort of 25 patients with clinical symptoms associated with 
GCA or PMR, a PET-scan of the thoracic, femoral and tibial 
arteries was performed and assessed using a four-category 
scoring system similar to the system used by Walter et al..[32] 
Vascular uptake in thoracic arteries was significantly more 
frequently observed (p<0.0001) in patients with GCA. Uptake in 
the thoracic arteries was associated with a sensitivity of 56% and 
a specificity of 98% for the diagnosis of GCA or PMR. Vascular 
uptake in the legs displayed a sensitivity of 64%, but a specificity 
of 77%. The authors speculate that this might be explained by 
the fact that arteriosclerosis is more frequently observed in the 
lower legs.
 These authors subsequently set up another study [34] to 
assess 18F-FDG uptake in different parts of the vascular system 
and the larger joints at diagnosis and after three and six months of 
corticosteroid therapy. 35 patients with proven GCA underwent 
a PET-scan, which was scored at seven different vascular 
regions using the same scoring system as applied in their previous 
research. This resulted in a so-called total vascular score (TVS) 
ranging from 0 (no regions involved) to 21 (all regions involved). 
At baseline 29 out of 35 patients showed vascular uptake, most 
frequently (74%) in the subclavian arteries. In contrast with 
the aforementioned research by Walter et al. [32], patients 
with vascular 18F-FDG uptake had a significantly lower ESR 
(p=0.039) compared to those without vascular uptake in this 
study. After three months of corticosteroid therapy, mean TVS 
dropped to 2.4 ± 3.5 compared to baseline (p<0.0005) in 14 
out of 22 patients who underwent a second PET-scan. After six 
months there was no further significant decrease in mean TVS 
in the 8 patients who still showed 18F-FDG uptake at this point. 
TVS did not differ significantly between patients who did and 
did not relapse.
 In line with the results of the study conducted by Walter et 
al. [32], Hooisma et al. [35] found that an elevated ESR was a 
statistically significant positive predictor for a positive 18F-
FDG-PET-scan in cases of confirmed large vessel vasculitis. 
Additionally, the presence of arthralgia was determined to be a 
statistically significant negative predictor of a positive 18F-FDG-
PET-scan. However, because these predictive effects were very 
weak, Hooisma et al. concluded that these parameters would be 
of little clinical relevance. 
 18F-FDG-PET was not found to be a sensitive diagnostic 
tool by Brodmann et al. [36], who hypothesized that like 
duplex ultrasonography, 18F-FDG-PET would be able to detect 
inflammation of small vessels such as the temporal arteries. 
However, 18F-FDG-PET was unable to detect inflammation in 
17 patients with GCA which only involved the temporal arteries, 
as confirmed by ultrasound. It should be noted that in accordance 
with the results found using ultrasound, PET did detect 
inflammation of the large vessels in all of the remaining 5 
patients, who only had extracranial manifestations of GCA. 
 Hautzel et al. [21] investigated the degree of 18F-FDG 
uptake in the thoracic aorta compared to uptake in the liver, which 
invariably shows homogenous uptake, as a reference organ. 
They quantified the maximal standardised uptake value 
(SUVmax) in predetermined regions of interest (ROI) in both of 
these organs. Subsequently, a cut-off ratio between these organs 
associated with an optimal sensitivity and specificity of the PET-
scan was determined using a receiver operating characteristic 
(ROC). The study involved a cohort of 18 GCA patients and two 
control groups. The participants in the first control group were 
age- and sex-matched patients who underwent a PET-scan for 
oncological reasons but had no history of malignant mediastinal, 
pulmonary or liver processes; the second control group contained 
age- and sex matched participants with at least one elevated liver 
enzyme value. Other inclusion criteria in this group were identical 
to those for the other control group. An optimal cut-off value was 
identified in a comparison between the GCA group and the first 
control group, corresponding with a sensitivity of 88.9% and a 
specificity of 95.1%. Applying this cut-off ratio to the control 
group with elevated liver enzymes revealed a specificity of 
95.6%. The authors did not provide a sensitivity in this study.
 Like Hautzel et al. [21], Prieto-Gonzalez et al. [19] determined 
sensitivity and specificity cut-off values for vascular inflammation 
as seen on PET/CT. A total of 32 patients were included, of whom 
17 had used corticosteroids for a maximum of three days prior 
to scanning. The control group was comprised of 20 patients 
undergoing PET-scans for oncologic reasons. ROIs for 18F-FDG 
uptake were four aortic segments and their loco-regional 
tributaries, all normalised to liver 18F-FDG uptake, and 
SUVmax was determined quantitatively at each of these ROIs. 
SUVmax at every ROI was significantly higher in GCA patients 
compared to controls. The optimal cut-off value (1.89) provided 
a sensitivity of 80% and a specificity of 79%. Patients with 
cranial symptoms presented significantly higher values of 
maximal and mean SUVmax than patients lacking cranial 
manifestations. In agreement with the studies by Hooisma et al. 
[35] and Walter et al. [32], mean SUVmax correlated with CRP 
levels.
 Besson et al. [20] attempted to identify a new semi-quantitative 
standard for assessing the presence of aortic wall inflammation 
in GCA on 18F-FDG-PET-scans. The study included 11 
patients with biopsy-proven GCA, 8 of whom were undergoing 
corticosteroid therapy, and 11 controls. ROIs investigated 
included the ascending aorta, aortic arch and descending 
thoracic aorta. In these regions the SUVmax of 18F-FDG was 
determined semi-quantitatively and normalised to either lung, 
liver or venous blood pool uptake. The aortic to blood pool 
uptake ratio was found to be the most discriminative between 
the two cohorts. When applied to the aortic arch this method 
provided the best diagnostic performance, providing a sensitivity 
and specificity of 82% and 91%, respectively. CRP levels were 
found to correlate with the amount of uptake of the ascending 
aorta in the GCA group, in consonance with research by Walter, 
Hooisma and Hautzel and their respective colleagues.[21,32,35]
 In a cohort including a total of 13 patients with GCA (n=10) 
or Takayasu’s arteritis (n=3), stratified by age, Henes et al. [22] 
found increased SUVmax of 18F-FDG in the ascending and 
descending aorta and supra-aortic branches in 9 out of 10 GCA 
patients. The one patient who did not have increased SUVmax 
was receiving steroid therapy when the PET-scan was performed. 
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However, 5 other patients in this group were also on steroid 
therapy during the PET-procedure. No patients in the control 
group, composed of 8 oncologic patients, showed pathological 
18F-FDG uptake. By means of our own calculations, we 
determined the sensitivity and specificity to be 90% and 100%, 
respectively.
Meta-analysis
Of the 9 articles selected for literature review, 4 were included 
in the statistical analysis. The remaining articles were excluded 
from analysis because they did not assess the diagnostic accuracy 
of PET in GCA in terms of specificity and sensitivity (Blockmans 
et al. (2006), Hooisma et al.), only compared the efficacy of PET 
with the efficacy of another diagnostic technique (Brodmann et 
al.), or analysed a heterogeneous cohort of patients with different 
types of vasculitis as opposed to GCA only, thus confounding 
the statistical data. (Blockmans et al. (2000), Walter et al.). The 
characteristics of the studies included in the meta-analysis are 
presented in table 1. The outcome of the meta-analysis is presented 
in figures 2 through 5.  Overall sensitivity was determined to 
be 85% (95% CI; 74-92%, I2=0.0%), overall specificity was 
determined to be 91% (95% CI; 82-96%, I2=31.2%), positive 
likelihood ratio was determined to be 7.18 (95% CI; 3.43-15.06, 
I2 =10.1%) and negative likelihood ratio was determined to be 
0.19 (95% CI; 0.11-0.33, I2= 0.0%).
discussion
At 85% sensitivity and 91% specificity, our own analysis 
confirms that PET is an accurate diagnostic tool for GCA. 
Although the resolution of PET has improved in recent years, 
visualisation of the temporal arteries remains very difficult 
because of the high uptake of 18F-FDG in the brain and the 
small size of the cranial vessels.[36,37] This limitation was also 
found by Brodmann et al. [36], who found that PET was unable 
to detect temporal inflammation but flawlessly identified 
extracranial involvement. 
TP = true positives, FP = false positives, TN = true negatives, FN = false negatives, CI = confidence interval, 
LR = likelihood ratio, SUVmax  = maximum standardised uptake value
Table 1 - Characteristics of studies included in meta-analysis.
  
  
 
 
  
  
 
  
  
 
 
 
  
  
 
 
 
Year
2014
2014
2008
2008
Design
Prospective, 
case-control
Retrospective, 
case-control
Retrospective
Retrospective, 
case-control
PET-scoring  
system
Mean of four 
SUVmax-values 
in four different 
aortic segments
SUVmax-ratio  
artery/liver, 
artery/lung and 
artery/venous 
blood pool
Maximum of six 
SUVmax-values 
measured in six 
arterial locations
SUVmax-ratio 
aorta/liver
TP  
26
9
9
16
FP  
4
1
0
2
TN  
16
10
8
34
FN  
6
2
1
2
Sensitivity 
(95% CI)
0.81 
(0.64-0.93)
0.82 
(0.48-0.98)
0.90 
(0.55-1.00)
0.89 
(0.65-0.99)
Specificity 
(95% CI)
0.80  
(0.56-0.94)
0.91
(0.59-1.00)
1.00 
(0.63-1.00)
0.94
(0.81-0.99)
Positive Likelihood 
Ration (95% CI)
4.06 
(1.66 - 9.91)
9.00 
(1.36-59.54)
15.55 
(1.04-232.22)
16.00 
(4.12 - 62.14)
Nagative Likelihood 
Ration (95% CI)
0.23 
(0.11 - 0.50)
0.20 
(0.06-0.71)
0.14 
(0.03-0.64)
0.12 
(0.03-0.44)
Study
Prieto- 
Gonzalez 
et al.
Besson et al.
Henes et al.
Hautzel et al.
Figure 2 - Sensitivity Forest Plot. CI = confidence interval
Figure 3 - Specificity Forest Plot. CI = confidence interval
Figure 4 - Positive Likelihood Ratio (LR) Forest Plot. CI = confidence interval
Figure 5 - Negative Likelihood Ratio (LR) Forest Plot. CI = confidence interval
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 The sensitivity of the biopsy procedure has been reported to 
vary between 67% and 97% (the most common value appearing 
to be around 80-85%)[15-17] but its specificity is often not 
reported. The sensitivity we found in our meta-analysis for 
PET appears almost identical. Because of the aforementioned 
difficulties in visualising the temporal arteries with PET, we do not 
recommend replacing temporal artery biopsies with PET as the 
first diagnostic modality of choice. However, PET might be 
very well suited to demonstrate GCA in patients with a negative 
biopsy but suspected extracranial involvement. PET could 
potentially reach even higher sensitivity and specificity in these 
cases because its limited ability to visualise the cranial vessels 
would be taken out of the equation.
 Several issues arise in the interpretation of our meta-analysis 
and the literature we base our recommendation on. First of all, 
no standard protocol for the scoring of PET scans currently 
exists. Several authors have attempted to design a novel scoring 
system in their research. Hautzel et al. [21] proposed the use of 
a semi-quantitative scoring system based on the ratio between 
the SUVmax measured in the aorta and the liver. However, in 
a head-to-head comparison between different semi-quantitative 
scoring systems by Besson et al. [20], the aorta to liver ratio 
was outperformed by the aortic to venous blood pool SUVmax 
ratio. The latter study was methodically superior (but used a 
significantly smaller cohort) because all patients had biopsy-
proven GCA, versus only clinical suspicion in the study by 
Hautzel et al. [21], and a carefully selected control group. For 
further research into the diagnostic performance of PET in 
GCA, we suggest the adoption of a semi-quantitative scoring 
system as opposed to a quantitative scoring system, because a 
semi-quantitative system generally achieves lower intra- and 
inter-observer variability.[38] We recommend the use of the aortic 
to venous blood pool SUVmax ratio using a cut-off value of 1.53, as 
proposed by Besson et al. [20], in order to achieve an optimal 
sensitivity and specificity.
 Several studies included in our review reported difficulties 
in distinguishing atherosclerosis from vasculitis on PET imaging. 
Atherosclerosis can produce an image similar to vasculitis, 
because increased macrophage metabolism in this disease process 
increases 18F-FDG uptake in the vessel walls. CT provides a 
solution in dealing with this difficulty, even without the use of 
intravenous contrast (which could introduce attenuation errors). 
Dunphy et al. [39] found that calcification found on CT and 
18F-FDG uptake rarely occur simultaneously within a vessel. 
This provides further rationale for the use of joint PET-CT as a 
diagnostic tool for GCA in future research.
Another problem with much of the pre-existing research in this 
field is that GCA is diagnosed inconsistently, based on either 
clinical criteria, a positive temporal artery biopsy or both. 
Because GCA shows significant clinical overlap with Takayasu’s 
arteritis and PMR, arbitrary stratification of patients in one of 
these groups is to some degree unavoidable. However, we argue 
that further research would significantly benefit from selection of 
patients with consistently defined GCA. As positive biopsies are 
currently the most accurate test, disregarding PET, we propose 
the exclusive selection of patients with positive temporal artery 
biopsies who fulfil the ACR-criteria for GCA in future research. 
These ACR-criteria are displayed in table 2.[40] 
As a direct consequence of the overlap between GCA and other 
rheumatic diseases, these disease entities are often pooled in 
analyses investigating the efficacy of PET in large vessel 
vasculitis. In our opinion, a disease-specific targeted approach is 
more desirable because it allows for the design of more accurate 
diagnostic protocols. In order to make our meta-analysis as 
accurate as possible, we excluded studies with heterogeneous 
cohorts, i.e. cohorts consisting of patients with multiple types 
of vasculitis. By doing so, we achieved consistently low 
heterogeneity in our analysis. With increasing understanding of 
the underlying mechanisms and pathology of these diseases, we 
expect more specific research to be available in the near future.
 Another point of note is that a considerable number of 
studies include patients who receive corticosteroid therapy 
during their participation in the study. As demonstrated by 
Walter et al. [32], the sensitivity and specificity of PET directly 
correlate with the degree of active inflammation (ESR/CRP) 
in a patient, with higher accuracy achieved at more active 
inflammation. Therefore, in clinical practice, PET might reach 
higher sensitivity because patients not yet on treatment will have 
highly active inflammation.
 Furthermore, many studies include only small cohort of 
patients, contain poorly matched or absent control groups and 
are retrospective in design. The consequence of such a design is 
that ideally only patients who have positive biopsies are studied. 
Whether there is a difference between the biopsy positive and 
negative GCA patients in terms of the development of 
extracranial manifestations is unknown and difficult to 
investigate. Future research would benefit from larger 
prospective, randomised trials with accurately matched controls. 
 With continuing improvement in radiation dosage, image 
quality and scan time, we expect the sensitivity and specificity 
of PET to rise even further in the nearby future. A breakthrough 
in medical imaging was the introduction of the hybrid PET-CT 
scan. An important disadvantage of PET-scans is that anatomical 
landmarks are very difficult or impossible to recognise. The joint 
use of PET and CT can overcome this obstacle, but CT examination 
can also be used for correction of attenuation on PET images. 
PET-CT is commonly used in oncology, especially in staging 
lung cancer and lymphomas.[41,42] Hybrid PET-CT could 
potentially provide higher diagnostic accuracy that PET alone in 
the diagnosis of GCA. However, using both imaging techniques 
could lead to a significant increase in radiation dose. Research is 
currently being undertaken on how to counteract this disadvantage. 
Rodríguez-Vigil et al. have reported that the use of low-dose CT 
is possible without compromising image quality.[43]
A patient is considered to have GCA if three of these five criteria are met.
Table 2 - 1990 ACR criteria for the diagnosis of GCA.
 
 
 
 
 
1. Age at onset 50 years or more
2. Newly developed (localized) headache
3. Tenderness of temporal artery or decreased pulse
4. ESR greater than or equal to 50 mm/hr
5. Temporal artery biopsy showing vasculitis
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Conclusion
 After consideration of the results of our literature review and 
meta-analysis, we conclude that PET cannot replace temporal 
artery biopsy as a diagnostic modality in GCA at the present time. 
However, when considering GCA in patients with a negative 
biopsy, PET may provide a valuable addition because of its 
ability to visualise extracranial involvement. In our meta-analysis, 
we found that PET has a sensitivity of 85%, a specificity 
of 91%, a positive likelihood ratio of 7.18 and a negative 
likelihood ratio of 0.19 for diagnosing GCA. These values will 
most likely not be directly applicable in clinical situations, 
because the exact accuracy of this diagnostic modality will vary 
with the circumstances in which it is used. PET will achieve a 
higher accuracy in patients with highly active inflammation (high 
ESR/CRP levels) and extensive extracranial inflammation, but 
lower accuracy in those patients who receive immunosuppressive 
treatment (such as corticosteroids). The diagnostic accuracy 
of PET could be improved further by the development of 
standardised scoring systems and the use of joint PET-CT. 
However, our meta-analysis proves that when used in the right 
circumstances, PET is a very accurate diagnostic modality when 
considering GCA in clinical practice.
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abstract
Objective: Information about the long-term survival and complications in patients after surgical repair of pulmonary valve 
stenosis (PVS) is important for defining an appropriate follow-up. We aim to provide a complete overview of long-term morbidity 
and mortality after PVS surgery at a young age. 
Methods: This systematic review compared studies with at least 15 years follow-up of patients who had surgery for isolated PVS at 
a young age. The primary outcome is long-term survival. The secondary outcomes are reinterventions, heart failure, arrhythmia, 
endocarditis and NYHA class. 
Results: Eight studies were included in this systematic review. Six studies showed a survival rate between 92% and 96% 
after a mean follow-up varying between 20 and 34 years in a total of 936 patients. Seven studies reported reinterventions for 
pulmonary valve regurgitation or restenosis. Arrhythmias were reported in seven studies and were divided in supraventricular and 
ventricular arrhythmias. Reintervention numbers differed between 2,6 and 52,8%. Most arrhythmias were ventricular 
arrhythmias, which was 24,4 % of the arrhythmias patients, 13,2% of the reported arrhythmias were supraventricular 
arrhythmias. Two out of 126 patients suffered from endocarditis. In a group of 522 patients 11 patients developed heart failure. 
The majority of patients were in NYHA class 1 (323 of 430 patients) at last follow-up.
Conclusions: Long-term clinical outcome in patients after surgical repair of PVS is good. However the incidence of reinterventions 
and arrhythmias is worth mentioning and therefore life-long follow-up with long intervals seems advisable.
Pulmonary valve stenosis, surgery, long-term outcome, survival, reintervention, arrhythmia, heart failure, endocarditis
Systematic Review
introduction
A congenital heart defect occurs in 0,8% of all live births in 
Europe (1). Pulmonary valve stenosis (PVS) is one of the common 
congenital heart defects with a prevalence of 10% in children 
with congenital heart defects (2).
 Surgery has been the treatment option for children with an 
isolated PVS for over 50 years. The surgical approach of closed 
valvulotomy was first performed in 1948. This evolved from 
open valvulotomy with inflow occlusion to open valvulotomy 
using cardiopulmonary bypass (3). In the last decades balloon 
valvuloplasty has taken over.
 Long-term clinical outcome of patients with surgical 
PVS repair is only infrequently documented. Many patients 
are discharged from routine follow-up. (4) Information about 
long-term outcome is important to define an appropriate follow-up 
for adult patients with an isolated PVS who have been operated 
in childhood.
 This article reviews literature about long-term outcome of 
surgery in children with isolated PVS. We aim to provide a clear 
and complete overview of survival and late complications, like 
reintervention, heart failure, arrhythmia and endocarditis. Also 
the functional class (NYHA-class) in this patient group is studied.
Methods
Search strategy
On the 13th of October 2014 a systematic literature search 
for relevant studies was conducted in Pubmed. We searched for 
pulmonal (valve) stenosis (Mesh or Tiab) in combination with one 
of the following terms: outcome, survival, reintervention, events, 
quality of life, heart failure, morbidity, arrhythmia or endocarditis 
(all tiab). We limited our search to humans and the English 
language. The exact search we performed was:  ((“Pulmonary 
Valve Stenosis”[Mesh] OR (pulmonary stenosis[tiab] OR 
pulmonary stenosis[tiab] OR pulmonary valve stenos* OR 
pulmonary valvular stenos*)) AND (outcome[tiab] OR 
survival[tiab] OR (re intervention[tiab] OR re interventional[tiab] 
OR re interventions[tiab]) OR events[tiab] OR quality of 
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life[tiab] OR heart failure[tiab] OR morbidity[tiab] OR 
arrhythmia[tiab] OR endocarditis[tiab]) AND (“humans”[MeSH 
Terms] AND English[lang]))).
In- and exclusion criteria
Articles had to have a long term follow-up of patients surgically 
treated for isolated PVS. To accomplish our search the following 
inclusion criteria were used:
- Patients had to be surgically treated for PVS
- Minimal mean follow-up duration of 15 years
- Patients had to be treated before 18 years of age.
 Studies were excluded when other heart defects were 
present, e.g. Tetralogy of Fallot or transposition of the great 
arteries, except for small atrial septum defect (ASD) or patent 
foramen ovale. 
Study selection
The titles and abstracts of the articles were screened by one 
of the researchers. The full-text articles were analysed by two 
researchers (BK and WvG) separately.
Outcome
As a primary outcome we analysed long-term survival. Secondary 
outcomes were: reinterventions, heart failure, arrhythmia,  endocar-
ditis and NYHA-class at last follow-up. NYHA-class is a functional 
classification for patients with heart failure. Parameters that are used 
are symptoms, limitations of physical activity and status of rest (5).
Data analysis
We only included articles when data on follow-up duration 
were provided or could be extracted from the articles. Percen-
tages were calculated if they were not given and if the data was 
suitable. Continuous variables were described as mean ± standard 
deviation (SD) or median with range.
 
results
Overview of the articles
Our search in Pubmed resulted in 631 articles. After applying 
the inclusion and exclusion criteria to title and abstract 593 
articles were excluded. Thirty-eight articles were fully read 
and all were included (2, 4, 6-11). Reference checking did 
not produce extra relevant articles. A flowchart including the 
reasons for excluding is presented in Figure 1. 
 The study characteristics of the eight articles included are 
presented in Table 1. The eight studies were all cohort studies. 
Each study included between 12 and 331 patients and all 
surgeries were performed between 1951 and 2009. All studies 
had a mean long-term follow-up of at least 19 years and at 
most a mean follow-up of 45 years. The studies were published 
between 1988 and 2013. Five studies mentioned the age of 
patients at operation (2, 4, 6, 7, 9). This was between 3 and 13.6 
years of age. Three studies reported the age at follow-up, Roos 
et al. (4) had a median age of 32 at follow-up and Vogel et al. 
(7) of 21 years. Moller et al (10) mentioned that the mean age at 
follow-up was 50.5 years. 
Primary outcome
Four studies with a mean follow-up of 22 to 34 years showed a 
survival between 94,6% and 96,0% (2, 4, 9, 11). Each of these 
studies included between 53 and 331 patients who had been 
operated from 1958 to 2009. The studies of Kopecky et al. (6) 
and Morris et al. (8) showed a survival of 92 and 93% after a 
mean follow-up of 20 to 24 years. These studies were published 
in 1988 and 1991 and both included a little over 190 patients 
who were operated between 1956 and 1989. Vogel et al. (7) 
included 12 patients operated between 1967 and 1973. After 
a mean follow-up of 19 years a survival of 100% was found. 
Moller et al. (10) described an overall survival of 84% after a 
mean follow-up of 45 years in a group of 73 patients operated 
between 1952 and 1961.
Reintervention
Seven of the eight studies included reported the number of 
reinterventions. Earing et al. (9) reported 28 reintervention in a 
patient group of 53 (52,8%) subjects, whereas Kopecky et al. (6) 
reported 5 reinterventions in his cohort of 193 patients (2,6%). 
The other studies showed a reintervention rate somewhere 
between these two studies (2, 4, 7, 10, 11). Morris et al. (8) did not 
mention the number of reinterventions in his patients. The most 
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Figure 1- Flow chart of study selection process.
*  syndrome is defined as Alagille syndrome, heterotaxy syndrome, Noonan 
syndrome, RAS/MAPK syndrome, Leopard syndrome, 12q14 deletion syndrome 
and twin twin transfusion syndrome.
**  other disease such as aorta stenosis, endocarditis, Ebstein anomaly etc.
TGA: transposition of the great arteries, TOF: Tetralogy of Fallot, VSD: ventricular 
septum defect, AV valve disease: atrioventricular valve disease. 
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frequently described reason for reintervention was pulmonary 
valve regurgitation, and sometimes it was pulmonary valve 
restenosis (2, 4, 9). 
Heart failure
Three of the eight studies reported the number of patients 
confronted with heart failure. Kopecky et al. (6) reported 2 cases 
of heart failure in a group of 191 patients (1,0%). Hayes et 
al. (11) mentioned 9 cases of heart failure in the 331 included 
patients (2,7%). Roos-Hesselink et al. (4) reported that there 
were no cases of heart failure in her patient group (n=90). 
Arrhythmia and pacemaker implantation
Six studies reported patients with arrhythmias in their 
follow-up (2, 6, 8-11). Morris et al reported one death caused 
by an arrhythmia (8). Supraventricular arrhythmias like atrial 
fibrillation or atrial flutter were reported in 27 of 205 (13,2%) 
patients who underwent an electrocardiogram (ECG) or 24-hour 
ECG monitoring (2, 9, 10). Ventricular arrhythmias such as 
premature ventricular contractions or ventricular tachycardia 
were reported in 85 of 347 patients (2, 9, 11). Roos-Hesselink 
et al. (4) did not find any patients with supraventricular or 
ventricular arrhythmia in 1990 or 2001 on 24-hour ECG 
monitoring. Vogel et al. (7) did not report any case of arrhythmia. 
Kopecky et al. (4) reported two permanent pacemaker 
implantations for tachycardia-bradycardia syndrome which we 
count in our secondary outcome for pacemaker and arrhythmia. 
Three studies reported the implantation of pacemakers. In total, 
pacemaker implantations were reported in 8 of 334 patients (4, 6, 9).
Endocarditis
Three studies mentioned endocarditis. Earing et al. (9) reported 
one case of endocarditis, so did Moller et al. (10). Roos-Hesse-
link et al. (4) reported that there were no cases of endocarditis in 
the patient group.
NYHA class
Three studies reported the number of patients per NYHA class 
(4, 9-11). Of a total of 430 patients, 323 were in NYHA class 
1 (75,1%), 50 in NYHA class 2 (11,6%), 48 in NYHA class 
3 (11,1%), and 9 in NYHA class 4 (2,1%). Roos-Hesselink 
reported NYHA classes in percentages: 67% had NYHA class 1, 
30% had NYHA class 2 and 3% had NYHA class 3. No patients 
had NYHA class 4 in the studies of Earing et al. Roos-Hesselink 
et al. and Moller et al. (4, 9, 10). Eleven of the 12 patients in 
Vogel et al. (7) were in NYHA class 1. One patient in Vogel et al. 
had a cerebral-vascular accident and has left hemiplegia. All patients 
in Kopecky et al. (6) considered themselves to be asymptomatic 
at the time of last follow-up, but no NYHA classes were reported. 
Voet et al and Morris et al did not report NYHA classes either (2, 8).
discussion
Our study suggests that the long-term outcome of patients with 
pulmonary valve stenosis who underwent surgery at a young 
age is excellent. Seven of the eight studies show a survival rate 
of over 90% at least 20 years after initial surgery. Vogel et al. 
showed an excellent survival rate of 100%, however. This 
number should be interpreted with caution as this concerns only 
12 patients, whichmakes this group less representative for the 
whole study. The study with the lowest survival is Moller et al. 
with 84% after 45 years. This study had a mean follow-up of 45 
years, the patients had a mean age of 50.5 years at the time of the 
last follow-up. The lower survival rate could be caused by higher 
age and some late complications such as heart failure after 
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Table 1 - study characteristics with primary outcome and secondary outcome
  
  
  
 
 
  
  
  
  
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Number  
of 
patients
191
12
192
331
53
90
79
73
Year  
published
1988
1990
1991
1993
2005
2006
2012
2013
Surgical  
era
1956-
1967
1967-
1973
1958-
1989
1958-
1969
1951-
1982
1968-
1980
1960-
2009
1952-
1963
Mean age 
at operation 
(years)
13.6 ± 13.1
3 ± 2.8
-*
-
10 ± 13
5.0 (median) 
range: 0-14
5.0 (median) 
range: 0-39
Mean 
follow-up 
(years) 
24 ± 4
19 ± 3
20
33
-
19
45
Median 
follow-up 
(range) 
24 (<1-30)
19 (15-23)
-
22 (16-29)
34 (18-51)
27 (22-33)
23 (0-45)
-
Survival 
 
92.0%
100%
93%
94.6%
96.2%
95.6%
96%
84%
Reinter-
vention
(n)
5/191 
(2.6%)*
1/12 
(8.3%)
-
14/277 
(5.1%)
28/53
(52.8%)
10/64 
(15.6%)
16/79 
(20.3%)
3/73 
(4.1%)
Heart 
failure 
(n)
2/191 
(1.0%)
-
-
9/331 
(2.7%)
-
0/90 
(0.0%)
-
-
Arrhythmia
(n)
2/191  
(1.0%)
-
1/192  
(0.5%)
81/215 
(37.7%)
23/53 
(43.4%)
0/64  
(0.0%)
4/79  
(5.1%)
1/73  
(1,4%)
Pacemaker 
(n)
2/191 (1.0%)
-
-
-
4/53 (7.5%)
2/90 (2.2%)
-
-
Endocarditis 
(n)
- **
-
-
-
1/53 (1.9%)
0
-
1/73 (1.4%)
NYHA Class 
(n)
-
class 1 (n =11)
-
1 = 228 (71%) 
2 = 39 (12.2%)
3 = 45 (14%)
4 = 9 (2.8%)
1 = 42 (82%)
2 = 8 (16%)
3 = 1 (2%)
4 = 0 (0%)
1 = 67% 
2 = 30% 
3 = 3%
4 = 0
-
1 = 53
2 = 3 
3 = 2 
4 = 0
Author
S.L. Kopecky 
et al, 1988 [6]
M. Vogel et 
al, 1990 [7]
C.D. Morris et 
al, 1991 [8]
C.J. Hayes et 
al, 1993 [11]
M.G. Earing 
et al, 2005 [9]
J.W. Roos-
Hesselink et 
al, 2006 [4]
A. Voet et al, 
2012 [2]
J.H. Moller et 
al, 2013 [10]
* The hyphen-minus means that the number was not mentioned in the article. **   Events are presented as number of events / total number of patients and in percentages
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longer follow-up. Year of surgery could be another explanation. 
The patients in this cohort were operated the earliest of all 
studies (1952-1963). Surgical techniques and perioperative care 
have improved since the start of open-heart surgery in the early 
50’s. This is why it is important to do more studies with 40-50 
year follow-up in this group of patients.
Secondary outcomes
Seven studies reported a considerable number of reinterventions. 
One study showed an reintervention rate of 52,8% in after 33 
years, this is more than half of the patients, whereas the lowest 
reintervention rate was 2,6%  in a study with a 24 years follow-up. 
This could possibly be explained by different definitions of 
reinterventions. The reason for reintervention is mostly 
pulmonary valve replacement for regurgitation and sometimes 
pulmonary valve re-stenosis.
 Only eleven heart failure patients were described in all articles. 
However five articles did not mention it. It is possible that the 
follow-up rate is too short to do a make prediction of heart failure 
numbers. The incidence of heart failure will increase with longer 
duration of follow-up and can be caused by compensatory 
mechanism based on right ventricular dilatation or by other 
factors such as aging with cell destruction and apoptosis (4).  
 We have found a great difference in numbers of arrhythmia 
between studies. Kopecky et al  showed a low rate of arrhythmia 
1,0%. A high number of arrhythmia was found in the study 
of Earing et al. with 37,7%. An explanation for the higher 
number of arrhythmia in some studies is probably the method 
of investigation: some studies incorporated 24-hour ECG 
monitoring while others did not. 
 Only eight pacemaker implantations were reported in 
334 patients (2,4%), therefore the need to implant a pacemaker 
after PVS surgery seems rare. Two cases of endocarditis were 
reported in all studies (9, 10). This suggests that endocarditis is 
also a rare complication.
Discussion exists about the clinical condition at longterm 
follow-up. Some studies report a limitation in some form of their 
physical condition. This was shown by the NYHA classes in the ar-
ticles of Hayes et al. Earing et al and Roos-Hesselink et al. On the 
other hand, other articles showed no physical limitations (6, 7, 10).
 Morris et al. did not report much about secondary outcomes 
except for arrhythmia. However, they have described the 
survival, our primary outcome, very well. The fact that this 
article reported many different congenital heart defects could 
be a reason for missing secondary outcomes. Meantime Earing 
showed higher numbers of complications. The higher number of 
the secondary outcome in this article may be caused by longer 
follow-up. However, this number of complications is much 
higher than that from Moller et al. which had a longer follow-
up. The explanation is probably the different definition of 
reintervention and arrhythmia. 
Limitations
This systematic review has a few limitations. Firstly, we did not 
do a statistical analysis of the raw data of all patients. Furthermore 
not all patients had at least 15 years follow-up. For example, in 
Voet et al. (published in 2012) the last patient was operated in 
2009 and thus had a follow-up of only 3 years. Nevertheless, 
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studies were included if the mean (or median) follow-up was 
over 15 years conform one of our inclusion criteria.
 Our review showed the importance of extensive follow-up 
including an interview, physical examination, electrocardiogram 
and echocardiogram. In this way a complete image of the 
patients will be acquired and thereby arrhythmias and 
pulmonary valve problems may be detected in time. Except for 
these complications there were no other common complications 
found which need specific attention.
 Nowadays surgery of PVS is not always the first choice 
of treatment because of the use of balloon valvuloplasty. 
According to Peterson et al. (12) surgical treatment produces 
lower long-term complications and lower number of reinterven-
tions. Despite these results, balloon valvuloplasty could well be 
the preferred therapy for PVS, because the intervention is less 
invasive, less expensive and requires a shorter hospital stay. We 
think more research is needed to determine which patients with 
PVS are best treated with balloon valvuloplasty or with surgery.
Conclusion
 Patients with PVS who undergo surgery at a young age 
have good long-term survival, but because of the incidence 
of reintervention and arrhythmia life-long follow-up with long 
intervals is advisable. 
references
1.  van der Linde D., Konings E.E., Slager M.A., et al. Birth preva-
lence of congenital heart disease worldwide: a systematic review and 
meta-analysis. Journal of the American College of Cardiology. 2011; 
58: 2241-2247.
2.  Voet A., Rega F., de Bruaene A.V., et al. Long-term outcome after 
treatment of isolated pulmonary valve stenosis. International journal 
of cardiology. 2012; 156: 11-15.
3.  Brock S.R. The Surgical Treatment of Pulmonary Stenosis. British 
heart journal. 1961; 23: 337-356.
4.  Roos-Hesselink J.W., Meijboom F.J., Spitaels S.E., et al. Long-term 
outcome after surgery for pulmonary stenosis (a longitudinal study of 
22-33 years). European heart journal. 2006; 27: 482-488.
5.  Momen N., Hadfield P., Harrison K., et al. Managing pain in advan-
ced cancer: a survey of United kingdom general practitioners and 
community nurses. J Pain Symptom Manage. 2013; 46: 345-354.
6.  Kopecky S.L., Gersh B.J., McGoon M.D., et al. Long-term outcome of 
patients undergoing surgical repair of isolated pulmonary valve ste-
nosis. Follow-up at 20-30 years. Circulation. 1988; 78: 1150-1156.
7.  Vogel M., Eger R., Klinner W., et al. Brock transventricular pulmona-
ry valvotomy in patients with pulmonary stenosis: long-term results. 
Pediatric cardiology. 1990; 11: 191-194.
8.  Morris C.D., Menashe V.D. 25-year mortality after surgical repair 
of congenital heart defect in childhood. A population-based cohort 
study. Jama. 1991; 266: 3447-3452.
9.  Earing M.G., Connolly H.M., Dearani J.A., et al. Long-term follow-
up of patients after surgical treatment for isolated pulmonary valve 
stenosis. Mayo Clinic proceedings. 2005; 80: 871-876.
10.  Moller J.H., Anderson R.C. A 43- to 54-year follow-up of 1,000 pa-
tients with congenital heart disease. The American journal of cardio-
logy. 2013; 111: 1496-1500.
11.  Hayes C.J., Gersony W.M., Driscoll D.J., et al. Second natural his-
tory study of congenital heart defects. Results of treatment of patients 
with pulmonary valvar stenosis. Circulation. 1993; 87: I28-37.
12.  Peterson C., Schilthuis J.J., Dodge-Khatami A., et al. Comparative 
long-term results of surgery versus balloon valvuloplasty for pulmo-
nary valve stenosis in infants and children. The Annals of thoracic 
surgery. 2003; 76: 1078-1082; discussion 1082-1073.
vol 5 - no 1 - October 2015 • Erasmus Journal of Medicine 21
Systematic Review
Clinical impact of single  
nucleotide polymorphism  
identification associated with 
the development of testicular 
germ cell cancer  
Jochem Boscha, Farhat Shalizia, Leendert Looijengab
a Medical student, Erasmus MC University Medical Center Rotterdam, the Netherlands
b Supervisor, Department of Medical Biology, Erasmus MC, Rotterdam, the Netherlands
Correspondence: Jochem Bosch, e-mail: 381138jb@student.eur.nl
abstract
Introduction: Although a strong genetic basis for testicular germ cell tumours (TGCT) has been found in previous studies little is 
known about the clinical impact of the possibility to detect this genetic basis.
Objective: Primary objective was to identify the impact, of the possibility to detect Single Nucleotide Polymorphisms (SNPs) as-
sociated with a higher risk for development of TGCT, on the clinical setting, using the known odds ratios (OR).
Methods: Pubmed search using the phrase: “Testicular Neoplasms/genetics”[Mesh] AND “Genetic Predisposition to Disease” 
[Mesh] AND (“Genetic Association Studies”[All Fields] OR “Polymorphism, Single Nucleotide”[Mesh]) was performed. From 
the 26 found articles were 19 articles excluded utilizing the formulated criteria.
Results: In this systematic review seven genome-wide association studies (GWAS), published 2010 or later, were analyzed resul-
ting in the finding of 28 of the 29 unique SNPs, which  had a significant OR with 95% CI. The SNPs rs1508595 (OR 2.69 (95% 
CI= 2.10-3.44)); rs3782179 (OR 2.71 (95% CI= 2.19-3.37)); and rs4474514 (OR 2.78 (95% CI= 2.23-3.45)) had the highest OR.
Conclusion: SNP variants are significantly associated with a higher risk of developing TGCT. People with these SNPs can be 
followed in time. In the near future this can lead to early detection and follow-up of patients with a high risk to developTGCT.
introduction 
Testicular germ cell tumour (TGCT) is the most common malig-
nancy in men aged 15–45 years.[1] The worldwide average in-
cidence of the disease is 1.5/100,000,[2] but rates vary between 
countries and ethnic groups. The incidence of TGCT is four to 
five times higher in men of European ancestry than in men of 
Asian or African ancestry (figure 1).[3] Over the past 30 years, 
the incidence of the disease has increased significantly from 
3.3/100,000 in 1975 to 6.9/100,000 in 2006 in the UK [4] and 
4.1/100,000 in 1975 to 6.6/100,000 in the US (figure 2).[5] Si-
milar trends are noted across most European countries.[6] The 
reasons for the increasing incidence in the Western countries 
remain unknown.
 The two main histological subgroups of TGCT are semino-
mas (50% of cases) and non-seminomas (40% of cases). About 
10% of TGCTs contain a mixture of both seminomatous as well 
as non-seminomatous histologies. The seminomas resemble the 
primary (embryonic) germ cells from which they are derived 
and the non-seminomas display varying degrees of differentia-
tion, from embryonal carcinoma, being the embryonic stem cell 
component, through to teratoma, fully matured somatic tissue, 
as well as extra-embryonic lineages, like yolk sac tumor and 
choriocarcinoma.[7] TCGT are believed to arise from primor-
dial germ cells (PGCs) or gonocytes via a pre-invasive phase 
of carcinoma-in situ (CIS).[8] For non-seminomas the peak of 
incidence occurs between the ages of 20 and 30 whereas semi-
nomas manifest a decade later.[9] TGCT are malignant tumours 
that easily metastasize. Nevertheless,the five-year survival rate 
exceeds 95%. The reason for this is the remarkable sensitivity to 
radiotherapy and/or chemotherapy of these tumours.[10]
 Risk factors for TGCT include previous germ cell tumour, a 
family history of TGCT, sub- or infertility and abnormalities of 
testicular development such as cryptorchidism.[7, 11] The risk 
of TGCT has been reported to be 8–10 fold higher in brothers 
compared with the general male population and 4-6 fold higher 
in sons of men who have had TGCT.[11, 12] These familial risks 
are higher than the approximately 2-fold familial relative risk 
observed in other cancers such as colorectal cancer. Previous 
studies support a strong genetic basis for TGCT.[13] But little is 
known about the clinical impact of this genetic basis for TGCT. 
Through this systematic review, the clinical impact of Single 
Nucleotide Polymorphism (SNP) variants associated with the 
development of TGCT in the population will be investigated. 
The possible SNPs found can, in the near future, be used for 
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early detection of patients with higher risk related to the deve-
lopment of TGCT. This could be done through Whole Genome 
Sequencing or another less expensive approach. 
Methods
A literature search was performed using Pubmed for articles pu-
blished in the English language. This search was performed on 
the 12th of January 2015. For finding the right articles the MeSH 
database was used to construct the following search phrase: “Tes-
ticular Neoplasms/genetics”[Mesh] AND “Genetic Predispositi-
on to Disease”[Mesh] AND (“Genetic Association Studies”[All 
Fields] OR “Polymorphism, Single Nucleotide”[Mesh]). Arti-
cles that mentioned the possible significance of the 
findings in clinical setting, for example the relative risk for 
TGCT development linked to the SNP, were included. Articles 
that were not available using the Erasmus MC account were ex-
cluded from the study. Furthermore, articles focussing on ad-
vanced stages of TGCT, non-genome-wide association studies, 
meta-analysis based on included articles or gene mutations other 
than SNPs were excluded. The in- and exclusion criteria were 
explicitly based on the titles and abstracts of the articles found 
with the search phrase. 
results
The Pubmed search produced 26 articles. Implementing the ex-
clusion criteria brought this number down to 7 (Figure 3). These 
articles gathered their information through genome-wide asso-
ciation studies (GWAS). GWAS studies typically focus on the 
association between SNPs and traits like TGCT. They compare 
large groups of individuals using a case-control setup which 
gives the articles a sizeable sample and power. In the included 
articles the common primary outcome was the odds ratio for de-
veloping TGCT. With this outcome a conclusion can be drawn 
about the clinical impact related to the possibility of analyzing 
SNPs associated to the development of TGCT.
 From GWAS analysis of 307,291 SNPs in 986 TGCT 
cases and 4,946 controls, Ruark et al [14] selected for follow 
up 694 SNPs, which they genotyped in a further 1,064 TGCT 
cases and 10,082 controls. They identified nine new loci sho-
wing association with TGCT. These nine loci, as can be seen 
in table 1, all have a significantly higher OR per allele (95% 
CI). Chung et al [15] analyzed 6 independent sample sets from 
which they conducted 3,211 affected individuals and 7,591 con-
trols. Five loci were selected (table 1) for further analysis and 
were located on different genes: HPGDS, MAD1L1, RFWD3, 
TEX14, RAD1C and PPM1E. The odds ratio of the UCK2 lo-
cus 1q23 was examined by Schumacher et al.[16] Two GWASs 
were used for the inclusion of 940 TGCT cases. Five SNPs on 
this locus were further evaluated (table 1) for significant asso-
ciation with TGCT risk. To address SNPs in the KITLG gene 
related to TGCT risk, Ferlin et al [17] used epidemiological data 
from GWAS. Two SNPs showed a significant correlation with 
an increase of risk for TGCT, rs995030 (OR = 2.38, 95% CI 
1.81-3.12) and rs4471514  (OR = 2.43, 95% CI = 1.86-3.17). 
Furthermore, Turnbull et al [18] performed GWAS utilizing 
samples from a total of 1643 cases of TGCT. Eight SNPs at six 
loci were found. Through manual cross-referencing four of these 
SNPs rs2736100 (OR = 1.36, 95% CI = 1.23-1.49), rs4635969 
(OR = 1.65, 95% CI = 1.47-1.86), rs755383 (OR = 1.57, 95% CI 
= 1.42-1.74) and rs2900333 (OR = 1.29, 95% CI = 1.17-1.43) 
were found in an earlier study of Turnbull et al [19] with the 
same OR’s and 95% CI’s. 
Figure 1 - World Age-Standardised Incidence Rates per 100,000 Popula-
tion, Males, World Regions.[14]
Figure 2 - TGCT incidence increasing in USA [5] (white) and UK popula-
tion.[4]
Pubmed articles (n=26)
Articles included (n=7)
Excluded (n=19)
• Not a GWAS study (n=10)
•  Gene mutations other than 
SNPs (n=2)
•  Advanced stages of TGCT 
(n=3)
•  Not accessible through EUR 
account (n=2)
•  No association with clinical 
impact (n=1)
•  Meta-analysis of included 
articles (n=1)
Figure 3 - Flow-diagram showing selection of articles for review.
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The other four SNPs all had a significantly higher OR per al-
lele (95% CI) compared to the control group (table 1). As said 
earlier, Turnbull et al [19]  performed an earlier GWAS with 
298,782 SNPs in 979 affected individuals. This study found four 
new SNPs related to a significantly higher OR per allele (table 
1). The last included article, Rapley et al,[20] is responsible for 
eight SNP markers on the SPRY4, BAK1 and KITLG gene. All 
these SNPs were also significantly linked to a higher OR per al-
lele for TGCT risk.
discussion
Most of the SNPs (28/29) analyzed in the 7 GWAS were signifi-
cantly associated with a higher risk to developing TGCT. People 
carrying at least one of these SNPs have a significantly increased 
chance to develop TGCT. 
 We performed a literature review to find SNP variants as-
sociated with TGCT development. In total, we examined 29 
SNPs which are located on different loci and therefore on dif-
ferent genes like KITLG, BAK1, SPRY4 and UCK2. Only 1 
SNP, rs12562047 located on locus 1q23, has a significant ne-
gative association with TGCT development (OR = 0.77, 95% 
CI = 0.68-0.87). This SNP variation will decrease the chance 
on developing TGCT compared to the normal population. Iden-
tifying rs12562047 through Whole Genome Sequencing will 
make these people less interesting to follow in time, because of 
their decreased chance to develop TGCT. 
 Our study gives an overview of current  SNPs related to the 
development of TGCT. Unfortunately, we could not implement 
all the known SNPs , because of our wide range of exclusion 
criteria. Three of our exclusion criteria, non-GWAS study, gene 
mutations other than SNPs and no association with clinical im-
pact, were based on the fact that they were not relevant for our re-
search question. Articles focusing on advanced stages of TGCT 
were also excluded. The reason for this is the irrelevancy to the 
clinical impact. Since TGCT is already proven, early detection 
is out of the picture. We included GWAS, because they make 
use of large population groups which provides a sizeable power, 
making the findings of a coincidental significance decline. The 7 
articles we included, conducted meta-analysis on large popula-
tion databases. One article performed a meta-analysis based on 
articles earlier published and was for this reason excluded. 
 In conclusion, SNP variants are significantly associated 
with higher risk to  develop TGCT and can in the near future be 
used to detect people with these SNPs so they can be followed 
in time resulting in an early diagnosis. This can decrease the 
intensity of the current heavy therapy, improving the quality of 
life and decreasing adverse effects in the future. SNP variant 
detection could be accomplished using Whole Genome Sequen-
cing or a more directed approach, which will be less expensive. 
Further research is needed to determine the number of SNPs 
negatively associated with TGCT development to specify people 
with a higher risk.
To include SNP detection in clinical settings we also need to 
know more about associations between different SNP variants. 
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abstract
Objectives: To determine whether there is a difference in incidence of herpes zoster in patients who had an organ transplantation 
and the normal population.
Methods: We used PubMed on January 6th, 2015 for relevant articles including the MeSH terms “Herpes zoster”, 
“Organ transplantation” and “Incidence”. The primary outcome was the number of herpes zoster cases. 
Results: The search produced 16 articles, of which 8 were included with a total 3257 patients. The mean incidence of Herpes 
zoster was 8.5%. The incidence of herpes zoster was significantly higher in the transplant group than in the normal population 
(OR: 19.7; 95%-CI 13.4- 29.0).
Conclusion: Our study showed that patients who have had an organ transplantation are significantly higher at risk to develop 
herpes zoster compared to the normal population (p<0.001).
Herpes zoster, VZV, Organ Transplantation, Incidence, Severity
Systematic Review
introduction 
Herpes zoster, also known as shingles, is a viral infection that 
affects the skin and the nervous system. This infection is caused 
by the varicella zoster virus (VZV), which can be airborne 
transmitted via respiratory droplets.[1] Primary infection usually 
occurs during childhood and results in varicella, known as 
chicken pox. After the primary infection, the virus becomes 
latent and establishes in the nervous system, specifically in 
the cranial nerve ganglia, dorsal root ganglia and autonomic 
ganglia. It may take years before the virus reactivates and 
presents as herpes zoster. Patients who are immunocompromised, 
such as HIV patients or patients who use immunosuppressants, 
are especially at risk of developing herpes zoster.[1] 
The skin lesions are characteristic for herpes zoster and important 
for early diagnosis due to its typical and distinctive clinical 
picture.  Since the virus moves down the nerve axon, it causes 
skin lesions in the corresponding dermatome and these lesions 
are distributed in a belt like pattern. Besides symptoms like pain 
and skin lesions, complications that might occur are post-herpetic 
neuralgia, vasculopathy, otitis, visual impairment, encephalitis. 
In some cases, when herpes zoster is diagnosed too late, it might 
even lead to death.[1] 
The incidence of herpes zoster in the European population 
between the age of 20 and 50 years, is 2.5 cases per 1000 
(0.25%) adults, the incidence in adults above 60 years  is 7.8 
cases per 1000 (0.78%) and within elderly adults over 80 years 
the incidence is 10 cases per 1000 (1.0%).[2] 
Patients who had an organ transplantation need to use 
immunosuppressants to prevent rejection of the transplanted 
organ. However, these medications cause the patient to be 
vulnerable for infections, such as herpes zoster. Over 90% of 
the transplanted patients are VZV seropositive, because of an 
infection in their childhood.[3] Yet, is uncertain how many 
patients develop herpes zoster after transplantation and whether 
it is more severe compared to the normal population. The 
purpose of this study is to investigate the incidence and severity 
of herpes zoster in transplanted patients.
Methods
Search Strategy 
We used PubMed as a medium to search for articles. At January 
6th 2015 we searched PubMed for the Medical Subject Headings 
(Mesh) term Herpes zoster in combination with the Mesh terms 
Organ Transplantation and Incidence. The exact search protocol 
was: ((“Herpes zoster” [Mesh]) AND “Organ Transplantation” 
[Mesh]) AND “Incidence”[Mesh]. 
Inclusion Criteria
Our inclusion criteria were: the subject of the study was organ 
transplantation and the incidence of herpes zoster after organ 
transplantation. Only articles written in English were included. 
Additionally, our search was limited to articles that were 
available for free in the Erasmus MC online library. Systematic 
Reviews, reviews, case reports and editorials were excluded. 
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Table 1 - Characteristics of included articles
  
  
 
 
  
  
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Type of 
Transplantation
Heart
Kidney 
Lung 
Liver 
Liver 
Lung 
Pancreas and 
kidney-pancreas
Solid organs
Population
175
319 
198 
209 
942 
239 
98 
1077
Cases
11 
16 
23 
25 
11 
29 
11 
90
Incidence (%)  
6.3
5.0 
11.6 
12.0 
1.2 
12.1 
11.2 
8.4
Severity  
7 cases: 1 dermatome
4 cases: 2 dermatome
No post-herpetic neuralgia
No hospitalisation 
Not mentioned 
18 cases: 1 dermatome
4 cases: disseminated cutaneous infection
1 case: visceral involvement
3 cases: hospitalised
26% post-herpetic neuralgia 
20 cases: 1 dermatome
5 cases: >1 dermatome
8 cases (31%): post-herpetic neuralgia 
10 cases: 1 dermatome
1 case: non visceral, disseminated cutaneous 
infection involving multiple dermatomes
8 cases: hospitalised 
27 cases: 1 dermatome
2 cases: disseminated cutaneous infection, 
non-visceral
20% post-herpetic neuralgia 
4 cases: 1 dermatome
3 cases: 2 dermatomes
3 cases: more than 2
4 cases: hospitalised
3 cases: post-herpetic neuralgia 
23/90 (26%) post-herpetic neuralgia
Author
Cabezón Ruiz et al, 
2003 [10]
Ce et al, 2012[9]
Fuks et al, 2009 [4]
Herrero et al, 2004 
[6]
Levitsky et al, 2005 
[7]
Manuel et al, 2008 
[5]
Netchiporouk et al, 
2013 [8]
Pergam et al, 2011 
[11]
Study Selection
The search was conducted by 3 independent reviewers. Following 
the initial search, titles, abstracts and full articles were checked 
for relevance. We investigated the incidence of herpes zoster in 
several organ transplants and the severity of the infection, more 
specifically, the number of dermatomes infected, the occurrence 
of post-herpetic neuralgia and whether or not the patient had to 
be hospitalized.
results
Literature search
Our PubMed search produced 16 articles. After applying the 
inclusion criteria, 8 articles were excluded and 8 articles therefore 
remained, which investigated the incidence of herpes zoster after 
organ transplantation. 
Study characteristics 
Among the included articles, two articles investigated herpes 
zoster after lung transplantation (Tx) [4, 5], two after liver Tx 
[6, 7], one after pancreas or kidney-pancreas Tx [8], one was 
kidney Tx [9], one after cardiac Tx [10] and one after several 
solid organs Tx [11]. Seven articles were based on one specific 
hospital or outpatient clinic and one article was based on over 
150 hospitals and nearly 900 outpatient clinics.[11] Follow-up 
ranged from 5 to 13 years. All articles were published after 2000. 
Population ranged between 98 and 1077 patients, which makes 
the  total population 3257. The characteristics of the articles are 
shown in Table 1. 
Incidence 
The incidence of herpes zoster ranged from 1,2 to 12,1%. 
Calculation showed an incidence of 8.48%. Severity was not 
mentioned in every article, but included affection between one 
and several dermatomes, disseminated cutaneous infection, 
post-herpetic neuralgia and hospitalization (see Table 1). 
After conducting a meta-analysis, the outcomes showed slight 
heterogeneity (p=0.04) (see Figure 1). 
Severity 
Six articles mentioned spreading of the virus.[4-8, 10] In these 
six articles, the total population was 1861, the total number 
of cases was 110 and the incidence was 8.87%. In 86 cases, 
one dermatome was affected, in 22 cases two or more 
dermatomes were affected (20%). In one case, there was visceral 
involvement.[4] 
Six articles mentioned post-herpetic neuralgia.[4-6, 8, 11] In 
these six articles, the total population was 1996 and the total 
number of cases was 189. The total occurrence of post-herpetic 
neuralgia was 17.2%. 
Four articles mentioned hospitalisation. [4, 7, 8, 10] In these four 
articles, the total population was 1413 and the total number of 
cases was 56. 15 of these cases led to hospitalisation.
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Figure 1 - Comparison of the incidence of herpes zoster-Forest plot for all studies with incidence as outcome. Each study is shown with a 95%-CI. 
The overall heterogeneity: Q=14.710, df=7, I2=52,4%, p=0,040 which shows there is a light heterogeneity
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Herpes zoster in normal population 
In the normal European population, the incidence of herpes 
zoster is 2.5 cases per 1000 adults between 20 and 50 years old.
[2] In adults between 40 and 50 years old, the age of most people 
in the studies we used, the incidence of herpes zoster is 1-4/1000, 
for our meta-analysis we used the incidence of 4/1000. In adults 
between 60 and 80 years old, the incidence is 7.8 cases per 1000 
(0.78%) and in elderly adults over 80 years old, the incidence 
is 10 cases per 1000 (1.0%). Immunocompromised patients are 
especially at risk with an incidence between 6 and 10%, 20 times 
higher than the normal population. Disseminated herpes zoster 
occurs in 2% of the cases, usually in patients with depressed 
cell-mediated immunity. The incidence of post-herpetic neuralgia 
varies between countries; in the United States, the incidence 
is 0.2% whereas in European countries, such as France, the 
incidence is 0.9%. 
In the Netherlands, the average annual hospitalisation incidence 
due to herpes zoster was 3.1 per 100,000 (0.0031%) between 
1994 and 2001.[12] The incidence was higher between 1994 
and 1997, at 3.6 per 100,000. The hospitalisation rate increases 
with age and is also higher for women than for men. This gender 
difference is mostly due to higher incidence among women 
in the age groups above 80 years, and was not the case in the 
younger age groups. 
discussion 
It has been known for a long time that patients are at risk of 
getting herpes zoster after organ transplantation. In this study 
our goal was to find out if the incidence of herpes zoster is higher 
in patients, that have had an organ transplantation, than in the 
population in average. In addition, we investigated if the herpes 
zoster in patients after organ transplantation was more severe 
than in the normal population. Our study showed a significantly 
higher incidence of herpes zoster in patients after organ 
transplantation (OR 19.7; 95% CI 13.4-29.0; p<0.001). 
Furthermore we concluded that more dermatomes are affected 
in patients after organ transplantation (20%) compared to the 
normal population (2%). There is also a higher incidence of 
post-herpetic neuralgia after organ transplantation (17.2%) 
compared to the normal European population (0.9%) and a 
higher incidence of hospital admissions in patients after organ 
transplantation (26.8%), compared to the normal Dutch 
population (0.0031%). 
Limitations 
Due to the use of MeSH terms, we might have missed studies that 
did not use herpes zoster as a MeSH term, but rather investigated 
all the adverse effects after organ transplantation and therefore 
still included the incidence and severity of herpes zoster. Also, 
there was a difference in the years of follow-up in the studies, so 
it is possible that patients got herpes zoster after ended follow-up, 
and that we therefore missed those data. Furthermore, our results 
show that there is a significant heterogeneity in the studies, but 
this heterogeneity is caused by one single study (Levitsky et al.), 
which makes us question the reliability of this study.
It is possible that a difference in the amount of immunosuppres-
sants given after organ transplantation is a confounder for the 
incidence of herpes zoster after transplantation. This is due to the 
fact that less immunosuppressants are given after kidney or liver 
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transplantation compared to lung or heart transplantation, which 
then decreases the risk of developing herpes zoster. A possible 
explanation for the difference in amount of immunosuppressants, 
is that lung tissue for example contains more lymphoid  tissue, 
which makes it more immunogenic. Thus, a higher doses of 
immunosuppressants is needed to prevent the transplant from 
being rejected. The clinicians are also very cautious with heart 
transplants, since the rejection of the organ is a major problem. 
To prevent the rejection, a higher doses of immunosuppressants 
is prescribed.
Another limitation is where the studies took place. Most of the 
studies were performed in the United States of America [1,5] 
and Canada [3,6] . The other studies took place in Spain [4, 8], 
Turkey [7] and Israel [2]. It is possible that the amount of drugs 
given to transplant patients differs between countries, so the 
incidence can vary.  This may result in a higher or lower 
incidence of herpes zoster. Since the treatment of the patients is 
not avalaible for us to view, it is difficult to conclude whether 
the incidence can be compared with the European or Dutch 
incidence.
Consequences 
In this study, we concluded that the incidence and severity of 
herpes zoster are higher after organ transplantation, compared 
to the normal population. Since the progress of herpes zoster 
is more severe in immunocompromised patients, it is important 
that doctors are aware of this fact. Therefore, it is advised that 
doctors monitor their patients for signs of herpes zoster after 
transplantation. If the infection is found and treated quickly, 
it can prevent loss of graft function. In this way, unnecessary 
retransplantation and donor organ waste can be prevented.  Also, 
before  a  patient is transplanted, a vaccine should be considered, 
however, the vaccine can have some adverse effects.  This is 
why it is only recommended in adults with evidence of immunity 
to varicella and  at least two months before the transplantation. 
At the moment, the vaccine is in use, yet there is still more 
research needed to confirm the advantages. [13]  
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abstract
Objective: To determine the effect of PYY3-36 on appetite in animals, specifically in mammals.  
Methods: A systematic search in PubMed using Medical Subject Headings (MeSH) terms for articles that focussed mainly on 
PYY3-36 (administration) itself (not other interventions) and its effect on appetite.
Results: The search term delivered 5 suitable articles, after applying the in- and exclusion criteria. All studies used mammals, 
4 used mice, only one used rats. All articles showed that PYY3-36 does suppress appetite to some extend/duration. The extend 
and/or the duration of this effect remains unclear, due to the incomparable study designs.
Conclusion: PYY3-36 has an appetite suppressive effect in mice and rats, but the extend of this effect has to be further investigated 
in future, more comparable studies.
introduction 
PYY, an amidated neuropeptide composed of 36 amino acids, 
postprandial secreted by L-cells in the ileum and colon within 
15 minutes after food intake. [1] L-cells are a type of intestinal 
enteroendocrine cells, they secrete PYY
1-36
 together with GLP-1; 
both are anorectic hormones.  
 There are two endogenous types of PYY, one of 
them is PYY
1-36
, which is the type secreted by the L-cells. 
The other, PYY
3-36
, is obtained by cleavage of the two terminal 
N-amino-acids of PYY
1-36
 by an enzyme called dipeptidyl-pepti-
dase-IV (DPP-IV). PYY
1-36
 levels are high during fasting, while 
PYY
3-36
 levels rise postprandial, peaking at about 90 minutes after 
eating. PYY
3-36
 levels remain elevated for up to 6 hours. 
PYY
1-36
 has affinity for 3 of the 5 known types of neuropeptide 
Y-receptors: Y1,2 and 5.[1] PYY
3-36
, which is the most 
bio-active form postprandial [2], is mainly active through the 
Y2-receptor. Rats, mice and humans are all mammals. It is 
thought that all these mammals have the same type of receptors, 
which would make it possible to use animals experiments to 
predict effects in humans. [3] However, according to 
Widdowson (1993) [4]: human brain contains primarily Y2 
receptors with few regions containing Y1 receptors whilst rat 
brain, as a whole, contains more proportionate amounts of Y1 
and Y2 receptors. So rat and human brain differ considerably 
regarding the distribution of NPY receptors. [4]  
  
 The Y2-receptor is mostly found in the following parts 
of the brain: amygdala, corpus callosum, hippocampus and 
subthalamic nucleus. The receptor is also detectable in the 
caudate nucleus, hypothalamus and substantia nigra.[4] In the 
hypothalamus lies the so called arcuate nucleus which plays a 
key role in appetite regulation.[5]
 It is suggested that the initial post-prandial release of PYY 
is under neural control, because the nutrients have not reached 
the small intestine and colon within 15 minutes after a meal 
when the levels of PYY are already rising. Further rise is most 
likely caused by the nutrients arriving in the distal intestine.[6]
 In conclusion: the anorectic effect is mostly mediated via 
the Y2-receptor and its interactions with the vagus nerve as well 
as the arcuate nucleus of the hypothamalus.[7] 
 Although PYY
3-36
 seems to decrease food intake, the 
reproducibility of the outcomes of some of the experiments 
is low [8,9]. Nevertheless, PYY
3-36
 might play a major role in 
the battle against obesity. Obesity is a major problem in the 
Western world and investing in research to PYY
3-36
 could lead to 
a solution. Therefore this review will focus on PYY
3-36
 to create 
more consensus on its effect on appetite in animals. 
Methods
Literature search
We performed a systematic search for articles about PYY and 
its effects on appetite in animals via PubMed on January 26th 
2015. We searched PubMed for the Medical Subject Headings 
(MeSH) term PYY, appetite and eating. Only English articles 
were taken into account and review articles had to be excluded. 
The exact search we used was: “Peptide YY”[Majr] AND 
(“Appetite”[Mesh] OR “Eating”[Mesh]) AND English[lang] 
NOT review[ptyp]. 
We had to opt for the ‘Free and Erasmus MC available’-articles. 
In- and exclusion criteria
Inclusion criteria: animal experiment mammals only, intrape-
ritoneal injection, study designs that investigated short-term 
effects <24 hours. The outcome of the trials had to be food 
intake in grams after injection. Exclusion criteria: not an 
original study, human subjects only, non-mammalian subjects, 
other administration than intraperitoneal, infusion instead of 
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injection or chronically administered PYY
3-36
, use of transgenic 
animals and articles that did not focus on our objective*. [*The 
effect of PYY (as an independent variable) on appetite (dependent 
variable) in animals.] For example, these articles focused on the 
effect of PYY on exercise or weight loss (instead of the appetite) 
or on the impact on other hormones such as insuline.  
  
Some studies aimed to examine the effect of a combination 
of PYY
3-36
 and another hormone or neuropeptide, in this case 
we examined properly whether these studies also contained 
measurements of PYY
3-36
 alone. Only these results were taken into 
account. Studies that contained any other ‘’non-physiological’’ 
interventions than the induction of diet obesity and adminis-
tration of PYY, were excluded (e.g. colectomy, vagotomy and 
brainpart ablations etc.).
Data extraction
We extracted relevant information from the selected studies. 
The data collection included the following study characteristics: 
animal species, number of animals (per group), obese or normal 
weight animals, time of fasting before injection, dose injection 
and time of measurements.
Of the studies that also evaluated the effect of another neuropeptide 
or the combination of another neuropeptide together with PYY
3-36,
 
we only included the ‘PYY’-only and control-groups.
results
Our PubMed search resulted in 154 articles, available for 
Erasmus MC. After applying the in- and exclusion criteria there 
were only 6 eligible articles [10-15] left. See Figure 1.
Study characteristics and outcome
All studies compared a certain dose of PYY, injected peritoneally, 
with a saline injection. The animals used in the studies were 
mice, only two used rats (Xu et al. (2010) and Batterham et al. 
(2002)). Remarkable was that 3 out the 4 studies that used mice, 
used the same type C57BL/6 (Moriya et al. (2009), Neary et al. 
(2008), Parkinson et al (2008)). 
 All studies measured food intake by weighing the 
difference of food that was given before the injections and at 
the food that was left on different timepoints in grams. Xu et al. 
(2010) and Moriya et al. (2009) used respectively both two kinds 
of rats and mice: normal–weighed (NW) and diet-induced-obese 
(DIO) rats and mice. Though, Xu et al. (2010) is the only study 
that used four different groups in total; not only NW and DIO, 
but also a fed state group vs. a group that fasted 20 h before 
injection. Thus, they used in total four different groups, 
which they acclimated daily for four days, before starting their 
experiment. Injections were given 09:00 AM. 
 An effect was only noticed in the rats that had fasted 
twenty hours before injection; de NW rats showed a significant 
reduction in their food intake during all the measurements (up 
to four hours). The DIO rats showed a significantly lower food 
intake only after the first hour.   
Moriya et al. (2009) showed a reduction of food consumption 
in a dose-dependent manner after administration at 18:00 PM 
(measurements at different concentrations). Up to four hours, 
a significant reduction was shown at a concentration of 3 mg 
kg−1, 1 mg kg−1  and 0.3 mg kg−1  in the NW mice. This is in 
contrast to the reduction shown in DIO mice, which was only 
measured at a concentration of 1 mg/kg. This study showed that 
the effect of food intake reduction of PYY(3-36) did not sustain for 
twenty-four hours. 
 The other study that only used rats (Batterham et al. (2002)
showed a dose dependent correlation between the food intake 
and the amount of injected PYY
3-36
; the higher the dose of 
PYY
3-36
, the more food intake was inhibited. The doses were 
PYY
3-36
 0.3, 3 and 10 µg /100 g. Injections were given just be-
fore onset of the dark phase, which is the beginning of the free 
feeding period of the rats. 
PubMed Search
n=194
Articles screened 
n=154
Articles read
n=8
Not available via 
Erasmus MC
n=40
Not an original article
n=15
Not focussed on 
review objectives
n=37
Non intraperitoneal 
administration
n=13
Only use of PYY 
analogs or Y2-R 
(ant)agonists
n=4
Excluded because of 
outcome not in grams
n=2
Human subject only
n=67
Non-mammalian 
animals
n=2
Infusion or only chro-
nic administration
n=3
Transgenic/knockout 
mouse
n=5
Included articles
n=6
Figure 1 - Flowchart Article
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     Next to Moriya et al. (2009), also Neary et al. (2008) 
investigated the dose-dependent effect of PYY
3-36
 injection on 
the food intake. They  distinguished two main groups: a low 
and a high dose group. The low dose group either received a 
dose of 3 nmol kg−1 (which was not significant) or a dose of 6 
nmol kg−1. The high dose group received 30 nmol kg−1 intrape-
ritoneally. All mice were injected at 09:00 AM. The subsequent 
timepoints showed no significant differences in food intake.
 Parkison et al. (2008) not only investigated the effect of 
PYY in freely fed mice or mice that fasted for a set period of 
time, but also examined whether a specific fasting time (0, 6, 
12, 18, 24 or 30 hours) before injection at 08:00 AM influenced 
the anorectic effect of PYY.  They used a set dose of 23 nmol 
kg−1.  
 Challis et al. (2003) used two different groups: freely 
fed mice and fasted mice, both were injected at 19:00 PM. This 
study only showed significant differences in food intake at 6 and 
24 hours. See table 1.
Conclusions
There is a lot of discussion whether PYY3-36 really suppresses 
appetite. With the aim to create some consensus about this 
matter, we performed this literature systematic review. 
 Concluded can be that PYY3-36 indeed has a suppressive 
effect on the appetite, however, the extend and/or the duration of 
this effect remains unclear, due to incomparable study designs 
(different variables e.g. doses, species and time of administration). 
discussion
Article selection
It was difficult to narrow down the amount of suitable articles. 
We could not add the terms ‘’NOT humans’’ or NOT clinical 
trial since some of the studies included an in study with human 
subjects.  
 Due to the fact that non-mammalian animals have different 
Y-receptors than humans, we ruled out studies that involved 
non-mammalian subjects.
We chose for intraperitoneal administration, because this 
imitates the physiology the most. Since PYY is produced in the 
gut. Intravenous administration would peak immediately after 
administration, which is less comparable to the physiological 
situation. [1] With the aim to select as comparable as possible 
articles, we only selected articles that used the outcome 
measurement of appetite in grams.
Limitations: training period
Not every article provided information about whether the animals 
were trained before the start of the experiment (Challis et al. 
(2003) and Neary et al. (2008)). 
In the studies that did mention this information, the training 
period varied from 2 days (Batterham et al. (2002)) till 4 weeks 
(Moriya et al. (2009)). 
 It is imaginable that a sudden change of circumstances is 
stressful for the animals. Stress can cause changes in certain 
hormonal levels. This might be of influence on the appetite 
suppressive effect of PYY3-36. [17] 
Limitations: time of injection and dose
Rats and mice are nocturnal animals, which means they also eat 
during the night-time.[17] As mentioned earlier, PYY
3-36
 levels 
rise postprandial. Thus, in rodents PYY levels are high in the late 
night and early morning, when freely fed.
In most experiments PYY
3-36
 was injected at 8:00 or 09:00 AM, 
when physiological levels are also high. 
Some (in) studies fasted the animals the night before 
administration, so the PYY
3-36
 levels of these fasted were also 
low.  Only two studies administered PYY
3-36
 PM, respectively 
18.00 PM (Moriya et al. (2009)) and 19.00 PM (Challis et  al. 
(2003)), when the endogenous PYY
3-36
 level is low.  
  Differences in outcomes between studies that injected PYY 
in the morning and studies that injected PYY in the evening, 
may be due to the difference in endogenous levels of PYY at 
different times. This also makes the studies less comparable. 
 Remarkable is that, one of the two studies that administered 
PYY PM, did not show a significant difference between food 
intake in PYY-mice and the control group (saline-mice). But all 
the studies that injected AM, did show significant decrease in 
food-intake some time after injection.  
 The cause of this difference remains unclear, since not 
only the time of administration but also the dose differs in the 
studies. 
 The use of different doses is another aspect that has to be 
addressed. The given dose of PYY
3-36
  differed between all the 
experiments. PYY
3-36 
effects seem to be dose dependent, as 
shown in Neary et al. (2008). So the found extend of the appetite 
suppressive effect, might be due to the use of a different dose.
Use of different rodents
While 4 out of 6 studies chose mice as subjects, only two studies 
chose rats. 
 Rats are not genetically identical, in contrast to mice bread 
for research. Consequently, interindividual differences are more 
likely to be found in the study that used rats. The fact that rats 
are not genetically identical makes them more comparable to 
humans, as humans are not genetically identical too. Using the 
same strands of mice would be the same as studying only one 
human being. Therefore, interindividual differences are to be 
expected.
Relevance of future research
The earlier mentioned limitations have led us to the conclusion 
that further research, with more comparable study designs, has 
to be carried out. This, to determine the extend and duration of 
the appetite suppressive effect of PYY
3-36.
  
 Answering those unknowns, might be the starting point 
of a treatment against obesity, a serious and fast growing health 
problem, with economic consequences, in well-developed 
countries.[18]
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Table 1 - Study characteristics and outcomes of included studies 
  
  
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Species & number 
of animals
Male normal-weight 
(NW) Sprague– 
Dawley rats (n=20) 
and male  
diet-induced-obese 
(DIO) Sprague- 
Dawley rats (n =20)
Male C57BL/6 mice 
(n=8-12 per group) 
Male C57BL/6  
wild-type mice  
(n=7-8/group  
low-dose) (n=10/
group high-dose)
Male C57Bl/6 mice  
(n = 8/group)
Male wild-type 129/J 
mice (n = 8/group)
Male Wistar rats 
(n=8/group)
Feeding
Ad libitum
NW: regular 
rat chow, 
DIO: high fat 
rat chow.
Ad libitum
NW: regular 
chow
DIO: high fat 
chow
Ad libitum,
fasted 18 
hours before 
injection 
Ad libitum;
fasted for 
increasing 
periods of 
time before 
injection of 0, 
6, 12, 18, 24, 
or 30 h 
Ad libitum; 
one group 
was freely fed 
and the other 
group fasted 
for 24 hours
Ad libitum; 
the group 
was freely fed 
in the dark 
phase
Dose PYY  
(or saline)
PYY3-36  
(300 µg kg−1   
bodyweight)  
or saline
PYY3-36 (0.3, 1 
and 3 mg kg−1) 
or saline
Low-dose study: 
mice received 
PYY  (3 nmol kg−1 
or 6 nmol kg−1) or 
saline
High-dose 
study:  mice 
received PYY3−36 
(30 nmol kg−1) or 
saline
PYY3-36 (23 nmol 
kg−1) or saline 
 
10 µg PYY/100 g 
of body weight or 
saline 
PYY3-36 (0.3, 
3 and 10 µg 
/100 g)  
or saline
Time of 
measurements
30 min, 1 h, 2 h,  
and 4 h after 
injection
2, 4, and 24 h after 
injection
1 h, 2 h, 4 h, 8 
h and 24 h after 
injection
1 hour, 2 hours, 
4 hours, 6 hours, 
and 24 hours after 
injection 
6 hours, 24 hours, 
and 48 hours after 
injection
Just before the 
onset of the dark 
phase 
Results  [PYY (3-36) measurement ±SEM 
vs saline measurement±SEM] Significant 
results only 
Freely fed rats: 
- DIO rats: no effect
- NW rats: no effect
Fasting  rats:
- NW rats: 
*  0.5 h:  4.04±0.27 g vs 5.35±0.39 g;  
P = 0.042; 
* 1 h: 4.78±0.43 g vs 7.3±0.8 g; P = 0.042; 
*  2 h: 6.89±0.47 g vs 9.26±0.83 g;  
P = 0.0047; and
*  4 h: 11.34±0.43 g vs 13.12±0.34 g;  
P = 0.023
- DIO rats:
* 1 h: 4.03±0.37 g vs 5.77±0.6 g; P = 0.031
*  2 h: 4.78±0.6 g vs 7.08±0.71 g; P = 0.04
NW mice:
- up to 4 hours:
* 0.3 mg kg−1: 0.77±0.08 g vs 0.91±0.07 g
* 1 mg kg−1: 0.59±0.05 g vs 0.91±0.07 g
* 3 mg kg−1: 0.51± 0.06 g vs 0.91±0.07 g
DIO mice:
- up to 4 hours:
* 1 mg kg−1: 0.82±0.06 g vs 1.01± 0.06 g
Low dose (6 nmol kg−1):
*  1 h: PYY significantly decrease food intake in 
in comparison to control
High dose (30 nmol kg−1):
* 1 h: 0.77±0.03 g vs 1.18±0.05  g
Non-fasted mice:
* 2-4 h: 0.06±0.01 g vs 0.13±0.02 g
Fasted mice:
- fasted for 6 hours:
* 1-2 h: 0.05±0.01 g vs 1.17±0.02 g
- fasted for 12, 18, 24 and 30 hours:
*  0-1 h: significant (no measurement 
available)
* 1-2 h: significant (no measurement 
available)
Freely fed mice:
* no significant measurements
Fasted mice:
*  6 & 24 h: significant (no measurement 
available)
Freely fed rats:
- up to 4 hours1:
*  0.3 mg kg−1: 7.14 g±0.36 g vs 8.21 
g±0.64 g
*  3 mg kg−1: 6.43 g±0.71 g vs vs 8.21 
g±0.64 g 
* 3 mg kg−1: 5.71 g±0.57 g vs 8.21 g±0.64 g
1 data extracted from figure 1 Batterham et al. (2002)
Study
Xu et al. (2010)
Moriya et al. (2009)
Neary et al. (2008)
Parkinson et al. 
(2008)
Challis et al. (2003) 
Batterham et al. 
(2002)
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Summary
Objective: This systematic review and meta-analysis aims to summarize the evidence of the efficacy and safety of non-vitamin K 
oral anticoagulants (NOACs) in the treatment of acute venous thromboembolism (VTE) compared to standard treatment with 
vitamin K antagonists (VKAs).
Methods: PubMed was searched for randomised controlled trials that investigated non-inferiority between a NOAC and a VKA 
in patients treated for acute VTE. Primary outcome had to be reported as recurrent VTE and related death. Safety outcome had 
to be major bleeding and clinically relevant non-major bleeding.
Results: 152 publications were identified and 5 publications were eventually included. The meta-analysis showed non-inferiority 
between NOACs and VKAs (RR 0.900 [0.773-1.05]) in recurrent VTE. The safety analysis showed significantly less major 
bleeding events (RR 0.604 [0.415-0.879]) with a relative risk reduction (RRR) of 39,6% and a significant decrease in clinically 
relevant non-major bleeding (RR 0.755 [0.578-0.985]) with a RRR of 24,5%.
Conclusions: NOACs are as effective as standard therapy in preventing recurrent VTE, but have a more favourable bleeding 
risk profile. 
introduction 
Acute venous thromboembolism is a common disease affecting 
1 to 2 in 1000 adults a year.[1,2] The condition often leads to 
hospitalisation, is known for its recurring properties and can 
be fatal.[3] Venous thromboembolism (VTE) is the third most 
common cardiovascular disease after myocardial infarction and 
stroke.[4] A VTE can present itself as deep-vein thrombosis 
(DVT) or pulmonary embolism (PE) or a combination of both. 
 The current standard treatment consists of initial parental 
anticoagulant therapy with heparin and overlapping 
administration of a vitamin K antagonist (VKA).[5] Though the 
conventional therapy is effective, it has significant disadvantages. 
Heparin needs to be injected, where VKA treatment requires 
laboratory monitoring of the international normalized ratio 
(INR) and frequent dose adjustment partly due to its complex 
interactions.[6,7] In addition, bleeding continues to be a substantial 
problem during VKA therapy. The risk of major bleeding after 
the first year of therapy associated with VKAs is still 1 to 2% 
per year.[6] 
 In the last decades several trials have been published on the 
role of so called non-vitamin K oral anticoagulants (NOACs) 
in the treatment of VTE. These drugs have a potent, direct 
effect on factor Xa or thrombin, are orally available and can be 
administered in fixed doses without the need for coagulation 
monitoring. A previous meta-analysis showed a favourable 
risk-benefit profile of NOACs compared to VKAs in patients 
with atrial fibrillation.[8] The objective of this review is to 
systematically review and summarize the evidence of the 
efficacy and safety of non-vitamin K anticoagulants in the 
treatment of acute venous thromboembolism.
Methods
The study aims to find all randomised control trials (RCTs) 
that investigated non-inferiority between a NOAC (edoxaban, 
rivaroxaban, dabigatran or apixaban) and a VKA (acenocoumarol, 
warfarin or phenprocoumon) in patients treated for acute 
VTE. Primary outcome had to be reported as recurrent venous 
thromboembolism and related death. In addition, the studies 
should examine the safety of NOACs in comparison with VKAs, 
expressed in major bleeding and clinically relevant non-major 
bleeding.
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Search
All records were identified through the electronic PubMed 
database till the 6th of January 2015 by using the following 
search strategy:
#1‘thromboembolism/drug therapy’ [MeSH] OR ‘embolism/
drug therapy’ [MeSH] OR ‘thrombosis/drug therapy’ [MeSH] 
OR ‘pulmonary embolism/drug therapy’ [MeSH] OR ‘venous 
thromboembolism/drug therapy’ [MeSH] OR ‘venous thrombosis/ 
drug therapy’ [MeSH]
#2 ‘dabigatran’ [Supplementary Concept] OR ‘dabigatran 
etexilate’ [Supplementary Concept] OR ‘rivaroxaban’ 
[Supplementary Concept] OR ‘apixaban’ [Supplementary 
Concept] OR ‘edoxaban’ [Supplementary Concept] OR 
‘anticoagulants/therapeutic use’ [MeSH]
#3 ‘warfarin’ [MeSH] OR ‘acenocoumarol’ [MeSH] OR 
‘phenprocoumon’ [MeSH] OR ‘anticoagulants/therapeutic use’ 
[MeSH]
#1 AND #2 AND #3
The additional filters used were ‘Randomized Controlled Trial’ 
and ‘English’.
Study selection and data extraction
Two reviewers independently determined the eligibility of 
retrieved studies according to predetermined criteria. 
The language restriction English was imposed. Inclusion criteria 
were:  an original RCT testing non-inferiority between a NOAC 
and a vitamin K antagonist, treatment indication had to be 
DVT or PE, objectively documented recurrent VTE as primary 
outcome, major and clinically relevant non-major bleeding as 
(secondary) safety outcome and adult study participants (18 
years or older). Bleeding was defined as major if it was overt 
and associated with a decrease in the hemoglobin level of 2 g 
per decilitre or more, required the transfusion of 2 or more units 
of blood, occurred into a critical site, or contributed to death. 
Clinically relevant non-major bleeding was defined according 
to the criteria of the Van Gogh Investigators as well.[9] The 
exclusion criterion was extended studies, because this review 
focused on the treatment of acute VTEs.
Quality assessment
A quality assessment was carried out with a combination of 
two common used quality assessment tools: Jadad[10] and 
Verhagen[11]. The constituted checklist consisted of the 
following questions: 1. Was there a description of concealed 
allocation? 2. Was a correct method of randomisation performed? 
3. Were the groups similar at baseline regarding the most 
important prognostic indicators? 4. Were the patients, care 
providers and outcome assessors blinded? 5. Was there a 
description of withdrawals and dropouts? 6. Was the primary 
outcome based on an intention-to-treat analysis? The answer 
‘YES’ provided two points, a ‘NO’ provided no points and a 
‘PARTIALLY’ gave one point. A score of ≥ 6 was considered 
satisfactory.
Statistical analysis 
The outcome measures were calculated as relative risk (RR) 
from the data available to correct differences in measurements. 
The meta-analysis regarding the primary efficacy outcome was 
carried out using a non-inferiority design feature. The aim of this 
methodology is to prove that a new treatment is not unacceptably 
less effective than the current standard treatment. A non- 
inferiority trail is different from a superiority trial for the reason 
that lacking evidence to reject a null hypothesis that states ‘there 
is no  difference between the two groups’, does not necessarily 
prove these groups to be equal. Because of that the meta- 
analysis regarding the primary efficacy outcome tested the 
hypothesis that NOACs would be non-inferior to the standard 
therapy with VKAs. To test this, a pooled RR estimate was 
calculated across the studies with an upper limit of the 95% 
confidence interval (CI) for the relative risk of 1.5 and a two- 
sided alpha level of 0.05. This margin corresponds to 
maintenance of at least 70% of the efficacy of the conventional 
VKA therapy. The secondary safety analysis was designed as 
an event-driven superiority test considering major bleeding 
and clinically relevant non-major bleeding. For major bleeding 
as well as clinically relevant non-major bleeding, the null 
hypothesis was formulated as: there is no difference in bleeding 
incidence between NOACs and VKAs in the treatment for 
acute VTE. For safety analyses, relative risk reduction (RRR) 
was calculated with the help of the RR (RRR=100% * (1-RR)). 
Heterogeneity among studies was assessed using Cochrane Q 
and I2 statistics. Data showing I2 values of 60 percent or more 
were considered heterogenic and therefore analysed using a 
random-effects model instead of the fixed-effects model.
Data were analysed using Open Meta-Analyst (BROWN: The 
Center for Evidence-Based Medicine).[12]
results
Study selection
The PubMed search identified 152 records. All records were 
screened by title and abstract for eligibility. Irrelevant records 
contained: subgroup analyses, tool development studies, study 
design publications, diagnostic research, dose testing and phase 
II trials, pilot studies, cost-effectiveness studies, studies on 
treatment length, studies with a different drug or drug comparison 
and studies with a different indication for treatment (e.g. atrial 
fibrillation, superficial thrombosis, orthopaedic surgery). 
Additionally, all records that were no original clinical trial were 
excluded. After full text evaluation of 12 articles, 5 articles 
met the inclusion criteria.[13-17] The flow diagram shows an 
overview of the study selection process (Fig. 1). 
Erasmus Journal of Medicine • vol 5 - no 1 - October 201536
Systematic Review
Study characteristics
The 5 studies included 24429 participants. The studies had 
been published between 2009 and 2013. The population size in 
the studies varied from 2539 to 8240. In the RCTs the study 
populations were equally distributed concerning the baseline 
characteristics including age and risk factors for recurrent VTE 
(previous VTE, known thrombophilia, comorbidity and active 
cancer). The INR target window was 2.0-3.0 in all studies. The 
follow-up time ranged from 3 months to 12 months. The RCTs 
were multi-centre trials, most studies were performed in more 
than 30 countries. All trials only included participants older than 
18 years. The characteristics of the studies are summarized in 
table 1. 
Quality assessment
All studies were identified to be of satisfactory quality (table 2). 
No study gave a description of concealed allocation. Further, the 
EINSTEIN Investigators trials on rivaroxaban were open-label 
in contrast to the other double-blinded studies, which might 
increase the chance of bias. Only the study on rivaroxaban 
regarding DVT contained a full explanation of the reasons 
for withdrawal and dropouts, though all studies gave notice of 
those. Intention-to-treat analyses were performed in variable 
forms. The EINSTEIN Investigators performed an original 
intention-to-treat analysis, where the Hokusai-VTE Investigators 
and Schulman et al. performed a modified version and Agnelli 
et al. did only carry out an intention-to-treat analysis for the 
patients of whom data of the complete treatment length were 
available. 
Meta-analysis
All five studies provided adequate data to calculate relative risks 
(RRs) and therefore were applicable for meta-analysis. 
Primary efficacy outcome
The studies set different margins to test non-inferiority. All trials 
showed significant non-inferiority between the NOAC and the 
conventional VKA according to their own margin. The margin 
set for this meta-analysis was 1.5 for the upper limit of the 95% 
CI. This was consistent with the margin used by the Hokusai-
VTE Investigators. The pooled RR estimate of recurrent VTE 
and related death across the studies included was 0.900 ( 95%CI: 
0.773-1.05) based on the fixed-effects model (Fig. 2). The 
upper limit of 1.05 did not reach the pre-set margin of 1.5, which 
showed non-inferiority of NOACs compared to VKAs. 
Table 1 - Study characteristics
  
  
 
 
  
 
 
 
 
  
  
 
 
 
 
 
 
Year
2010
2012
2013
2009
2013
Number of patients
Intervention 
1731
2419
4118
1274
2691
NOAC
Rivaroxaban
Rivaroxaban
Edoxaban
Dabigatran
Apixaban
VKA & heparin 
Enoxaparin 
and warfarin or 
acenocoumarol
Enoxaparin 
and warfarin or 
acenocoumarol
Enoxaparin or 
unfractioned 
heparin* and 
warfarin
Unfractioned 
heparin* and 
warfarin
Enoxaparin and 
warfarin
Placebo*  
None
None
VKA and NOAC
VKA and NOAC
Heparin, VKA 
and NOAC
Study
EINSTEIN  
Investigators
EINSTEIN-PE  
Investigators
Hokusai-VTE 
Investigators
Schulman et al.
Agnelli et al.
Control 
1718
2413
4122
1265
2704
Follow-up length 
Intented treatment 
duration (3, 6 or 12 
months)
Intended treatment 
duration (3, 6 or 12 
months)
12 months
6 months
6 months
* Heparin was given in both groups
Table 2 - Quality assessment
  
 
 
 
 
 
Quality score
8/12
7/12
8/12
8/12
7/12
Study
EINSTEIN Investigators, 2010
EINSTEIN-PE Investigators, 2012
Hokusai-VTE Investigators, 2013
Schulman et al., 2009
Agnelli et al., 2013
Figure 1 - Flowchart of the study selection process
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Safety outcome
The secondary safety outcome was divided in major bleeding 
and clinically relevant non-major bleeding. The pooled RR 
estimate for major bleeding was 0.604 (95%CI: 0.415-0.879) on 
the basis of the random-effects model (Fig. 3). This resulted in 
a relative risk reduction (RRR) of 39,6% compared to patients 
receiving standard therapy. Because the 95%CI of the pooled 
RR estimate for major bleeding did not contain 1, this result 
corresponds to a substantial and highly significant risk reduction. 
 Judging from the random-effects model the merged RR 
estimate from clinically relevant non-major bleeding was 0.755 
(95% CI: 0.578-0.985), that corresponds with a relative risk 
reduction of 24,5%. Because the 95% CI of the RR estimate did 
not contain 1, this result was considered significantly different as 
well. Other adverse events were equally distributed between the 
intervention and control groups.
discussion
This systematic review and meta-analysis showed that 
non-vitamin K oral anticoagulants are as effective as standard 
therapy with vitamin K antagonists in preventing recurrent 
venous thromboembolism (VTE) and related death in patients 
with acute VTE (0.900 [95% CI: 0.773-1.05]).  Furthermore, 
patients with acute deep-vein thrombosis or  pulmonary embolism 
treated with NOACs have significantly less major bleedings 
(0.604 [95% CI: 0.415-0.879]). This stands for a substantial 
relative risk reduction (RRR) of 39,6% compared to patients 
receiving standard therapy. In addition, the risk of clinically 
relevant non-major bleeding drops in NOAC therapy (0.755 
[95% CI: 0.578-0.985]) by 24,5% (RRR). This further supports 
the hypothesis that NOACs have a more beneficial bleeding 
profile regarding both major bleeding and clinically relevant 
non-major bleeding. So NOACs are just as effective and even 
safer than VKAs in the treatment of patients with acute VTE. 
Table 1 - Study characteristics
  
  
 
 
  
 
 
 
 
  
  
 
 
 
 
 
 
Figure 2 - Recurrent venous thromboembolism in patients treated with non-vitamin K oral anticoagulants versus vitamin K antagonists
Figure 3 - Major bleeding in patients treated with non-vitamin K oral anticoagulants versus vitamin K antagonists
Figure 4 - Clinically relevant non-major bleeding in patients treated with non-vitamin K oral anticoagulants versus vitamin K antagonists
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 Ruff et al. already compared the efficacy and safety of 
NOACs versus warfarin in the treatment of patient with atrial 
fibrillation.[8] They found NOACs to be non-inferior to VKAs 
in treatment of patients with atrial fibrillation with respect to 
efficacy, like the present study did for the treatment of patients 
suffering from acute VTE. Regarding safety, Ruff et al. found 
a significant reduction in all-cause mortality and intracranial 
bleeding in patients with atrial fibrillation treated with NOACs 
compared to patient receiving warfarin, which none of the five 
studies of the present meta-analysis did. The concerns of Ruff 
et al. regarding increased gastro-intestinal bleeding in NOAC 
treatment were not confirmed by our data in patients with VTE. 
Further, their study found a relative risk reduction of 14% in 
major bleeding, which did not reach significance level.  In contrast, 
the analysis of the data on VTE treatment resulted in a significant 
relative risk reduction of 39,6% for major bleeding and 24,5% 
for clinically relevant non-major bleeding. Clinically relevant 
non-major bleeding was not analysed separately by Ruff et al.  
Limitations
The studies showed somewhat difference in treatment protocol 
and blinding methods. Hokusai-VTE Investigators and Schulman 
et al. gave heparin in the control as well as in the intervention 
group and used sham INR monitoring. 
Also, the EINSTEIN Investigators used an open-label 
design for both of their studies, where the other researchers 
did not. Besides that, the follow-up duration differed 
among the studies ranging from 3 to 12 months. Some 
depended on the duration of treatment, others did not. 
Those factors might give rise to variation among the studies 
compared in the meta-analysis. We only collected records 
through PubMed, which could have led to selection bias, 
although PubMed contains all relevant studies published in 
high-quality journals. The margin for the upper limit 95% CI 
was chosen based on clinical considerations. We considered 
that a margin of 1.5 was the maximum tolerance level, appro-
priate to prove non-inferiority. This choice was supported by the 
fact that 1.5 was the lowest limit in all studies we examined. 
Heterogeneity of the clinically relevant non-major bleeding 
analysis was substantial. Reasons for that could be found in 
differences in pharmacodynamics and pharmacokinetics among 
the different substances. Another factor that might play a role 
is the difference in interpretation of the definition of clinically 
relevant non-major bleeding.
Recommendations
Based on our research we recommend the implementation 
of  NOACs  in the treatment of patients with acute venous 
thromboembolism. The clinical value of NOACs consists of 
less major and clinically relevant non-major bleeding events 
during treatment with a similar risk of recurrence of the disease. 
The clinical and social implications of bleeding, especially 
those of major bleeding (e.g. cranial bleeding), are extensive, 
which involves costs as well. Therefore, this recommendation 
might need research, in particular on finances, to prove that 
implementation of NOACs has a favourable cost-benefit ratio. 
We think the medical advantages of the NOACs can justify the 
possible extra costs required for implementation.
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abstract
Objective: Tenofovir disoproxil fumarate (TDF) is widely prescribed for the treatment of HIV infection, despite the considerable 
risk of renal impairment. However, the reversibility of TDF-induced nephrotoxicity has not been determined systematically.
Methods: PubMed was searched in January 2015. Randomized controlled trials and cohort studies were included if they 
compared eGFR after discontinuation of TDF therapy with eGFR at baseline in HIV-positive patients.
Results: One randomized controlled trial and four retrospective observational studies were included. The majority of studies 
reported improvement of eGFR after discontinuation of TDF therapy in more than half of the participants.
Conclusion: eGFR should be thoroughly monitored during TDF therapy in HIV-positive patients, since, after discontinuation, 
TDF-induced nephrotoxicity appears to be partly or even completely reversible in most of those patients.
introduction 
In 2013, 35 million people were living with human immuno-
deficiency virus (HIV) worldwide, of which 12.9 million (37%) 
had access to antiretroviral therapy.[1] Combination antiretrovi-
ral therapy (cART) has dramatically declined mortality in HIV-
infected patients, by achieving sustained virological suppression 
to restore and preserve immunological function and prevent 
opportunistic infections.[2-5] 
Next to HIV-infection itself and pre-existing comorbidities, 
toxicity of certain antiretroviral drugs can play an important 
role in organ damage. Some protease inhibitors (PIs), such as 
indinavir and atazanavir, and nucleoside reverse transcriptase 
inhibitors (NRTIs), including adefovir and cidofovir, have been 
associated with nephrotoxicity.[6-8]
 
Tenofovir disoproxil fumarate (TDF), a NRTI, is recommen-
ded for use in combination with other antiretroviral agents, for 
the treatment of HIV-1 infection.[9,10] TDF is widely prescri-
bed due to its superior antiviral efficacy, low pill burden and 
relatively few side effects.[10,11] Despite low incidence of 
serious renal adverse events in registrational clinical trials 
[12,13], TDF has been linked to renal impairment in 4% of HIV-
infected patients [14-17]. Developing nephrotoxicity, defined as 
a decline in estimated glomerular filtration rate (eGFR), can lead 
to discontinuation of TDF therapy.[18] Since kidney disease 
in HIV-infected persons is associated with increased mortality, 
the aim of this review was to systematically determine whether 
TDF-induced nephrotoxicity is reversible.[19]
“tenofovir”[Title] AND (“nephrotoxicity”[Title] OR “renal 
function”[Title] OR “renal dysfunction”[Title] OR “renal 
damage”[Title] OR “kidney toxicity”[Title] OR “renal toxicity”[Title] 
OR “renal failure”[Title] OR “kidney disease”[Title] OR “kidney 
failure”[Title] OR “renal safety”[Title] OR “renal adverse 
events”[Title] OR “renal dysfunction”[Title] OR “nephropathy”[Title] 
OR “renal impairment”[Title] OR “glomerular filtration rate”[Title] 
OR “eGFR”[Title] OR “GFR”[Title]) AND (“reversibility”[All 
Fields] OR “reversible”[All Fields] OR “irreversible”[All Fields] 
OR “irreversibility”[All Fields]) AND (“humans”[MeSH Terms] AND 
English[lang])
Methods
In January 2015, PubMed was searched using different 
synonyms of tenofovir, nephrotoxicity and reversibility. No 
restrictions on the publication date were imposed. The search 
was limited to articles written in English. The exact search 
strategy is presented in Appendix 1.
Only studies with HIV-positive patients were included. 
Furthermore, explicit data on eGFR (quantified in ml/min/1.73 
m2) at initiation or directly after discontinuation of TDF therapy 
and during follow-up after discontinuation had to be given.
Case reports and review studies were excluded.
The risk of bias was assessed based on the number of patients, 
selection bias and adequate follow-up.
Appendix 1 - Search strategy
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results
A total of twelve studies were identified following the 
PubMed search. After assessment of titles and abstracts, four 
studies were excluded for the following reasons: case report [20], 
review study [21], no HIV-positive patients [22] – to research a 
homogeneous population – and no explicit data on eGFR [23]. 
We subsequently excluded three out of the eight remaining 
studies based on full text for the following reasons: no explicit 
data on eGFR after discontinuation of TDF therapy [24,25] or 
at all [26]. The analysis therefore included five studies.[27-31] 
Figure 1 shows the flow diagram of the study selection. 
One randomized controlled trial [28] and four retrospective 
observational studies  [27,29-31] were included, published 
between 2010 and 2014. Study characteristics are presented in 
Table 1.
A total of 13,263 participants were included in the studies. 
Sample sizes of included studies ranged from 21 to 13,007. The 
median age of the participants across all studies ranged from 40 
to 56 years. 81% of the participants were male. Median time 
on TDF therapy ranged from 13.2 to 39 months. One study 
included 13,007 participants, but only 601 discontinued 
TDF therapy and experienced a decline in eGFR during TDF 
exposure.[27] Another study included 58 participants, of which 
24 discontinued TDF therapy and completed 11.1 months 
of follow-up.[28] Two out of five studies did not mention 
median eGFR at initiation of TDF therapy.[28,29] However, one 
of those studies only included patients who started TDF therapy 
with eGFR ≥60 ml/min/1.73 m2.[29] Median eGFR at initiation 
of TDF therapy across the three other studies ranged from 74 to 
94 ml/min/1.73 m2.[27,30,31] 
Table 1 - Study characteristics
  
 
  
 
 
 
  
 
 
 
 
Year
2012
2014
2013
2010
2012
Journal
Antiviral Research
The Journal of Infectious Diseases
PLoS ONE
Journal of Acquired Immune Deficiency Syndromes
Journal of Infection and Chemotherapy
Country
Spain
United Kingdom
Japan
Australia
Japan
Author
Bonjoch et al.
Jose et al.
Nishijima et al.
Wever et al.
Yoshino et al.
Study type 
Retrospective 
observational
Retrospective 
observational
Randomized 
controlled trial
Retrospective 
observational
Retrospective 
observational
Table 2 - Participants’ characteristics
  
 
 
 
  
 
 
 
  
 
 
 
Number of participants
183
13,007
Patients who discontinued TDF and experienced 
a decline in eGFR during TDF: 601 
58
Patients who discontinued TDF and completed 
follow-up: 28
24
21
Gender, 
male/female 
157/26
10,550/2,457
28/0
24/0
20/1
Median (IQR) 
time on TDF, 
months
39 (22-63) 
31.2 (18-57.6) 
37.6 (25.2-51.7)
30 (14-42) 
13.2 (0.23-48.5)
Author
Bonjoch et al.
Jose et al.
Nishijima et al.
Wever et al.
Yoshino et al.
Median (IQR) 
age, years 
44 (40-50) 
40 (34-46) 
44 (37-51) 
56 (49-63) 
45 (25-61) 
Median (IQR) eGFR 
at initiation of TDF, 
ml/min/1.73 m2
-
94 (81-108) 
-
74 (61-88) 
74.7 (48.1-289.3) 
Records identified
through database
searching
Records screened
(n = 12)
Full-text articles assessed
for eligibility
(n = 8)
Studies included in 
qualitative synthesis
(n = 5)
Records excluded based
on title/abstract
(n = 4)
Full-text articles 
excluded with reasons
(n = 3)
Figure 1 - Flow diagram of study selection process
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Ethnic backgrounds were not well defined in multiple studies. 
The characteristics of the participants are presented in Table 2. 
All included studies evaluated eGFR. However, different 
equations were used to derive eGFR: Chronic Kidney Disease 
Epidemiology Collaboration equation [27], Modification of 
Diet in Renal Disease equation [29,31] and Japanese Society of 
Nephrology equation [28,30]. 
Four out of five studies compared eGFR during follow-up 
after discontinuation with eGFR at initiation of TDF therapy.
[27,29-31] One study compared eGFR during follow-up after 
discontinuation with eGFR directly after discontinuation of TDF 
therapy, since no other data were available.[28] Median follow-
up after discontinuation of TDF therapy varied between 11.1 and 
30 months.
The definition of reversibility differs between the studies. 
Therefore, we took mild improvement and normalisation of 
eGFR together into account as total improvement. Definition 
of improvement varies between an increase of >1 ml/min/1.73 
m2 in eGFR and eGFR recovery to ≥20% of the level at TDF 
initiation. Only one study distinguishes between patients with a 
pre-existing decline in eGFR and patients without a pre-existing 
decline, based on eGFR slopes.[27] The study details on TDF 
and eGFR are presented in Table 3.
 
Only one study calculated the power, but did not have sufficient 
participants.[28] The four other studies did not calculate the power.
[27,29-31] Two of those studies have small numbers of participants 
[30,31], the other two studies included a large number.[27,29]
Table 3 - Study details on TDF and eGFR 
  
 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Baseline
eGFR at TDF 
initiation
eGFR at TDF 
initiation
eGFR directly 
after TDF 
discontinuation
eGFR at TDF 
initiation
eGFR at TDF 
initiation
Median follow-up, 
months
22.5
(13-49.5)
26.4  
(14.4-45.6)
11.1
13 
(7-35)
30.2
(4.6-65.5)
Definition of 
normalisation
eGFR >60 mL/min/1.73 m²
Pre-existing decline in eGFR: eGFR 
within 5% of predicted eGFR based 
on eGFR slopes
No pre-existing decline: eGFR within 
5% of the eGFR at the time of TDF 
initiation
eGFR recovery to 100% pre-TDF
eGFR recovery to 100% pre-TDF
Author
Bonjoch et al.
Jose et al.
Nishijima et al.
Wever et al.
Yoshino et al.
Definition of mild 
improvement
Increase in eGFR until 
60 mL/min/1.73 m²
-
>10% improvement in 
eGFR from baseline
Increase in eGFR
>1 ml/min/1.73 m2
eGFR recovery to 
≥20% of the level at 
TDF initiation
In two out of five studies, selection bias was present.[28,29] 
These studies only included patients with normal renal 
parameters at initiation of TDF therapy, or did not present data 
on these parameters. The other three studies included both 
patients with and without pre-existing renal impairment.[27,30,31]
All of the studies had an adequate follow-up. In general, the 
studies have lost few patients to follow-up. One study did not 
mention how many patients were lost to follow-up.[31]
 
Three out of five studies have included around twenty partici-
pants [28,30,31], whereas the other two studies have included 
considerably more participants [27,29]. The studies with a small 
number of participants show respectively improvement of 11% 
[28], 100% [31] and 76% [30], while the studies with a large 
number of participants show percentages closer to each other, 
respectively 68% [29] and 61% [27].
In four out of five studies, more than half of the participants show 
any improvement in eGFR after discontinuation of TDF therapy.
[27,29-31] Improvement in eGFR is presented in Table 4.
discussion
Lately, serious renal adverse events of TDF are described, 
associated with increased mortality. Therefore, the aim of our 
review was to determine whether TDF-induced nephrotoxicity 
in HIV-positive patients is reversible. The outcomes state that 
TDF-induced nephrotoxicity is partly or even completely 
reversible after discontinuation of TDF therapy in more than half 
of the cases. Four out of five studies support this conclusion.
Table 4 - Improvement in eGFR
  
 
 
 
 
 
 
Number of 
participants
185
601
28
24
21
Normalisation†
108 (58%)
137 (23%)
-
10 (42%)
9 (43%)
Total improvement
126 (68%)
369 (61%)
3 (11%)
24 (100%)
16 (76%)
Author
Bonjoch et al.
Jose et al.
Nishijima et al.
Wever et al.
Yoshino et al.
Mild improvement†
18 (10%)
232 (39%)
3 (11%)
14 (58%)
7 (33%)
No improvement
59 (32%)
232 (39%)
25 (89%)
0 (0%)
5 (24%)
† The definitions of normalisation and mild improvement differs between studies (Table 3).
Table 1 - Study characteristics
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[27,29-31] This suggests that eGFR should be evaluated in HIV-
positive patients who receive TDF therapy and when a decline is 
measured, patients should discontinue TDF.
Our review had a few limitations. One of which is the small 
number of patients included in three out of five studies.
[28,30,31] This could influence the outcome and therefore, we 
considered this as an increased risk of bias. A second limitation is 
selection bias. Three out of five studies have included both pa-
tients with and without pre-existing renal impairment.[27,30,31] 
The other two studies have not, or data on renal function at 
initiation of TDF is not presented.[28,29] A pre-existing decline 
in eGFR might affect the percentages of mild improvement and 
normalisation of eGFR. Another limitation is the way eGFR 
is derived in the studies. Three kinds of equations were used, 
which makes it difficult to compare the studies. Moreover, all 
five studies use different criteria for both mild improvement 
and normalisation. One study uses eGFR directly after 
discontinuation of TDF therapy, instead of eGFR at initiation of 
TDF therapy, as baseline.[28]
Factors we did not study, but most likely have an influence on 
reversibility are such as, but not limited to: time on TDF therapy, 
gender and age. These factors are investigated in several studies, 
but since those are secondary outcomes, we did not research 
them.
In conclusion, future studies should investigate whether 
pre-existing renal impairment influences reversibility of 
tenofovir-induced nephrotoxicity.
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abstract
Objective: To conduct a systematic review of recent literature in order to assess the relationship between maternal migration and 
the risk of autism in children. 
Methods: The PubMed/MEDLINE database was searched for articles published in the English language between January 1, 2000 
and January 16, 2015. Only primary investigations examining the correlation between autism risk and immigration of the mother 
were included. The remaining studies were systematically reviewed by all authors independently and after screening of references 
articles that matched the inclusion criteria were added.
Results: Six articles were included, five of which showed a significantly higher risk of autism in children born to immigrant 
mothers. Only the results of the retrospective cohort study of 943,664 children have showed no significantly increased risk of 
autism (RR 1.4, 95% [CI] 0.9-2.4).
Conclusions: Children of immigrant mothers have an increased risk of autism. This knowledge is important for an early diagnosis 
of autism because maternal migration could be consided as a sik factor.
introduction
Autism
Autism is a neurodevelopmental disorder characterizedbyim-
pairedsocial interaction, abnormalities in social communicatio-
nandrepetitive, stereotypical patterns of behavior (1). Because of 
an incidence of  1/1,000 births which is still rising (2), autism is
largely considered to be one of the most common severe neu-
rodevelopmental conditions. Despite extensive research, the 
etiology of the condition remains unclear. In the past, only envi-
ronmental factors were thought to cause autism. More recently, 
genetic predisposition as well as de novo mutations are conside-
red to contribute to the manifestation of the condition. Although 
the genetic basis of Systematic review, Jan 2015 the disease is 
well-studied, the individual phenotype still cannot be explained 
using this model alone (3). Therefore the cause of autism is consi-
dered multifactorial and the exact pathogenesis remains unknown.
Environmental factors
Sixmajorenvironmentalfactors associated with a higher risk of 
childhood autism were identified and explored in a comprehen-
sive meta-analysis by Gardener et al.(4). An increased risk of 
autism was related to 50 factors in total, either in combination or 
alone,  which influence the risk of autism. The variation could be
explained by six major factors. These six major environmen-
tal factors identified in the study, were advanced parental age 
at birth, maternal prenatal medication use,  bleeding during 
pregnancy, gestational diabetes, being firstborn versus third or 
later born, and, important in the light of our present review, 
having a mother born abroad (4).
Maternal immigration
In light of the increasing number of first, second and third 
generation immigrants in Western countries, maternal 
immigration could be considered an increasingly important 
risk factor for autism. Autism is underdiagnosed in children 
from ethnic minorities (5). Early diagnosis, however, is of great 
importance for treatment of this disorder. The epidemiology of 
many diseases among immigrants is not well-studied yet and 
could be considered a new research area. Studies published 
before April 2007 were previously reviewed by Gardener et al. 
Besides, numerous perinatal and neonatal factors were analy-
zed in the meta-analysis. As this new research area has shown 
rapid progress, more studies published recently focused on the 2 
association between autism and maternal immigration. The 
purpose of this study is to provide a systematic review of 
recent literature on the association between autism and maternal 
immigration, offering the first summary of the latest articles 
exploring this environmental factor.
Methods
Literature search
The search was performed using the specific controlled 
vocabulary of this database (Medical Subject Heading terms). 
The search included the key words ‘autistic disorder’ in 
combination with ‘emigrants and immigrants’ or ‘emigration 
and immigration’ or ‘human migration’ or ‘secondgeneration’ or 
‘maternal immigration’ or ‘emigrationand ‘immigration/statis-
tics and numerical data’ as major topic.
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inclusion
The PubMed/MEDLINE database was searched for articles 
published from January 1, 2000 through August 31, 2015. 
Articles published in the English language and available on 
PubMed were used.  
results
Thirty-five articles were identified using this search strategy 
(Figure 1). After screening of abstracts and titles 27 articles were 
excluded. Full text of the remaining eight articles was reviewed 
and three more studies focusing on the diagnostic process and 
challenges among immigrants and behavioral problems as a 
whole, were excluded. After screening of references, one more 
study was identified that met all inclusion criteria and it was 
therefore included. In total, six articles examining the risk of 
autism in children of immigrants were identified and reviewed 
systematically.
 The studies were clustered per study type in order to 
facilitate the comparison and analysis of the results. We will 
discuss all included studies in turn. In the case-control study 
of Lehti et al.(6) (Table 1) children from second-generation 
immigrants (n=1132) in Finland, born by the year 2007, were 
compared with children who have two Finnish parents (n=4515). 
Information of the autistic children, parents and control group 
was collected from the Finnish Hospital Discharge Register, the 
Finnish Medical Birth Register and the Finnish Central Population 
Register. Matching of controls and cases was performed by 
the child’s date of birth (+/- 30 days), sex, region of birth, and 
residence in Finland. The risk of childhood autism was increased 
for those with two immigrant parents (OR 1.8, 95% [CI] 1.2-2.7) 
and for those with only an immigrant mother (OR 1.8, 95% [CI] 
1.2-2.7). Children with parents born in several areas (Vietnam, 
former Soviet Union and former Yugoslavia) 4 were associated 
with the highest risk, respectively aOR 7.0, 95% [CI] 2.3-21.2, 
aOR 1.7, 95% [CI] 1.05-2.9 and aOR 1.8, 95% [CI] 1.2-2.9). 
The second study, a retrospective case-note analysis of Keen 
et al. (7) (Table 2),included children diagnosed with autism- 
spectrum disorder presenting to the child development services 
in Lambeth or Wandsworth in the United Kingdom (n=428). 
35 records identified 
through data research and 
screened
8 full-text articles  
reviewed
5 full-text records  
assessed for eligibillity
6 studies included in  
qualitative synthesis
27 records excluded 
because they were secon-
dary publications (n=2) 
or did not examine the 
risk of autism (n=24) in 
humans (n=1)
3 records excluded be-
cause they examined the 
diagnostic process (n=2) 
or behavioral problems 
as a whole (n=2)
1 article included after 
screening of references
Figure 1 - Flow chart of studies for analyzing infantile autism and maternal 
immigration
Table 1 - Study characteristics of case control studies, analysing the autism risk in children born to immigrant mothers.
  
 
 
 
 
 
 
 
 
Country
Sweden 
Sweden 
Finland
Cases
157
408 
1132
Risk factors
Maternal age at delivery, maternal country 
of birth, maternal parity at delivery, maternal 
smoking in early pregnancy, background and 
features child. 
Maternal characteristics, pregnancy and delivery 
complications, infant characteristics. 
Parental immigration status, parental region and 
country of birth
Author (year)
Haglund et al. 
(2011) 
Hultman et al. 
(2002) 
Lehti et al.  
(2013)
Control
68964 
2040 
4515
OR, 95% CI
2.7, 2.0-3.7 
3.0, 1.7-5.2* 
1.8, 1.2-2.7*
*adjusted for confounders, such as parental age, parity, gestational age, birth weight, birth length.
Table 2 - Study characteristics of retrospective case note analysis, analysing the autism risk in children born to immigrant mothers.
  
 
 
 
 
 
 
 
 
Country
UK
Sample size
428
Variables
Demographic characte-
ristics, region of birth and 
ethnic group of mother
Author (year)
Keen et al. (2010)
Setting
Examination of the hypotheses that maternal 
ethnicity and/or immigration are linked to 
childhood ASD in the second generation
aRR*, 95% CI
Lambeth
7.92, 5.39-11.6b
10.01, 5.53-18.1c
3.97, 2.01-7.84d
Wandsworth
3.27, 2.36-4.53b
8.89, 5.08-15.5c
2.08, 1.33-3.25d
* adjusted relative risk. b Relative risk, specified for mothers born in Africa. c Relative risk, specified for mothers born in Caribbean. 
d Relative risk, specified for mothers born in Asia
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Although the child development teams in these two boroughs in 
London were different, they used the same diagnostic method 
and provided the same services. All children diagnosed between 
1 September 1999 and 31 August 2005 participated in the study, 
if they were resident and born in the United Kingdom. Mothers 
born outside Europe had a significant higher risk of having a 
child with an autism-spectrum disorder compared with those 
born in the United Kingdom, with the highest risk observed.
 Examination of the hypotheses that maternal ethnicity 
and/or immigration are linked to childhood ASD in the second 
generation Demographic characteristics, region of birth and 
ethnic group of mother Lambeth 7.92, 5.39-11.6b 10.01, 
5.53-18.1c 3.97, 2.01-7.84d for the Caribbean group (Lambeth: 
RR 10.01, 95% [CI] 5.53-18.1/ Wandsworth: (RR 8.89, 95% 
[CI] 5.08-15.5). Children with an African mother had the second 
highest risk (Lambeth: RR 7.92, 95% [CI] 5.39-11.6/ Wands-
worth: RR 3.27, 95% [CI] 2.36-4.53)and children with Asian 
parents had the third highest risk (Lambeth: RR 3,97, 95% [CI] 
2.01-7.84/Wandsworth: RR 2.08, 95% [CI] 1.33-3.25). Also 
Black mothers born in the United Kingdom had a significant 
higher risk compared with white mothers (RR 3.85, 95% [CI] 
2.12-6,99). The risk of autism was not increased in children 
born to immigrants from Western countries. In the case-control 
study of Hultman et al. (8) (Table 1) all Swedish children born 
between 1974 and 1993 and registered in the Swedish Birth 
Register were included. A total of 408 cases of children who 
were diagnosed with infantile autism were compared with 2040 
matched controls. Controls were matched to cases by age, year 
and hospital of birth. Maternal immigration was not the only risk 
factor 5 analyzed in this study. Hultman et al. found that the risk 
of autism was associated with maternal birth outside Europe and 
North America (OR 3.0, 95% [CI] 1.7-5.2). No further analysis 
of the ethnicity of the mother was performed. In the prospective 
cohort of Lauritsen et al.(9) (Table 3) a total of 943,664 children 
born in Denmark and younger than ten ears were followed from 
1994 through 2001 and various risk factors were assessed at 
baseline, such as maternal immigration. Children were followed 
from their first birthday or January 1994, until onset of autism, 
their tenth birthday, death, emigration or 2001. Of all children 81 
8 developed autism. The risk of autism increased if the mother 
was born outside Europe (RR 1.42, 95% [CI] 1.10-1.83). The 
risk was not higher if the mother was born in Europe (RR 1.02, 
95% [CI] 0.75-1.39). It was increased if the parents were not 
born in the same country (RR 1.36, 95% [CI] 1.08-1.76).
 In the case-control study of Haglund et al.(10) (Table 1) 
250 children participated who were born in Malmö, Sweden and 
were diagnosed with autism or Asperger syndrome. All children 
were born during 1980-2005 and they enrolled at the local 
Child and Youth Habilitation Center. The researchers found that 
maternal birth outside the Nordic countries (Scandinavia) 
was positively associated with autism (OR 2.2, 95% [CI] 
1.6-3.1). The highest risk estimated for autism was found among 
children to women who were born in Sub-Saharan Africa 
(OR 7.3, 95% [CI] 1.6-3.1). This risk was significantly higher 
than the risk in children born to mothers from other regions 
(p=0.007). The aim of the retrospective cohort of Van der Ven et 
al.(11) (Table 3) was to estimate the risk of developing autism-
spectrum disease in children born to immigrants as compared 
with children of Dutch-born parents. A total of 150 children di-
agnosed with autism-spectrum disorder were included. Loss to 
follow-up occurred mainly because of emigration 6 and 13,8% 
of the participants did not finish the study. Van der Ven et al. 
found that children with migrant parents appeared to have an 
increased risk, but there was no significant difference between 
the risk in children born to Dutch-born parents and children born 
to immigrants (RR 1.4, 95% [CI] 0.9-2.4). The authors state 
that the study may have lacked the power to reveal significant 
differences in the incidence of autistic disorders as a function of 
parental migrant status. The restricted number of cases (n=150) 
also prevented in-depth analysis. 
 
discussion 
This systematic review aimed to provide a summary of recent 
literature on the relationship between autism and maternal 
immigration. Overall, this systematic literature review found 
consistent evidence that…. there is an association between 
maternal immigration and the increased risk of having a child 
with autism. Five out of six studies positively associated maternal 
birth outside Europe with autism. One found an increased 
but non-significant risk if the mother was born in developing 
countries (e.g. Turkey, Morocco, Suriname and Dutch Antilles).
Possible explanations
There are several theories which explain The association 
between maternal migration and a higher risk of autism. In 1996, 
Gillberg and Gillberg (1996) (12) suggested that children with 
mothers born outside Sweden had an increased vulnerability to 
intra-uterine infections because their mothers were non-immuni-
zed migrants. However, there is not enough evidence to confirm 
or reject this hypothesis. Besides, the role of the immune system
in autism has been supported by earlier studies. Secondly, 
it is assumed that autistic men tend to travel abroad to seek a 
female partner due to the observation that their lack of social 
skills would be less obvious in foreign countries. Haglund et 
al. (2011) (10) did not find support for the two theories above 
as well as Lauritsen et al. (2005) (9). Also, there might be an 
Table 3 - Characteristics of cohort studies, analyzing the autism risk in children born to immigrant mothers.
  
 
 
 
 
 
 
 
Country
Denmark 
NL
Study type
Pro-
spective
Retro
spective
Setting
Investigation of the effects of 
risks of autism, of which some 
are related to family factors.
Examination whether a history 
of parental migration influenced 
a child’s risk of being diagnosed 
with ASD and ASD subtypes.
Author (year)
Lauritsen et al. 
(2005)
Van der Ven et al. 
(2013)
Cases
818 
150
RR, 95% CI
1.42,
1.10-1.83
1.4,
0.9-2.4
Variables
Family history of psychiatric dis-
orders, place of birth of child and 
age of parents, paternal identity. 
Paternal and maternal age at 
birth, parental country of birth.
Table 1 - Study characteristics of case control studies, analysing the autism risk in children born to immigrant mothers.
  
 
 
 
 
 
 
 
 
Table 2 - Study characteristics of retrospective case note analysis, analysing the autism risk in children born to immigrant mothers.
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association between vitamin D deficiency and autism(13), which 
could explain the association found in this review. Vitamin D 
deficiency in dark skinned immigrants is caused by a reduced 
exposure to sun in Northern countries and prenatal exposure to 
vitamin D deficiency might increase the risk of having an infant 
with autism.
However, there is no convincing evidence that vitamin D 
deficiency is the main cause of the increased risk for 
autism in children of black women and only one of the studies 
examined in this systematic review could provide evidence for 
this hypothesis, so additional research is required. Exposure to 
environmental hazards in country of origin might support this 
relationship as well. Lehti et al. (2013), who focused on former 
Yugoslavia, former
Soviet Union and Vietnam, mentions these factors since these 
countries had been in war during their research period. One 
of those environmental hazards is Agent Orange, a very toxic 
herbicide used during the Vietnam War. Polychlorinated 
biphenyls (PCBs) and depleted uranium are environmental toxics 
used in the Balkan wars. Even though there is no evidence to 
support the hypothesis that exposure to these materials cause 
neuro developmental problems in the long term, this should be 
considered as a possible explanation. Further investigation is 
needed. Another possible explanation could be intrauterine 
Toxoplasmosis. Toxoplasma gondii is associated with a higher 
risk of schizophrenia and schizophrenia is associated with an 
elevated risk of autism. This risk factor has been discovered 
recently and may be this is the reason it was not included in any 
of the reviewed articles for they examined other potential hazards 
during pregnancy and birth. 
 It could also be possible that the prevalence of autism is hi-
gher in non-Western countries. This could explain why children 
of non-Western mothers are more likely to be diagnosed with 
autism. However, the prevalence rates of autism in non-Western 
countries seem lower than the incidence rates in Western coun-
tries so the origin of the mothers could not explain the findings 
in this research.
 Psychosocial stress during migration is also mentioned to 
be a cause of this association. It has been suggested that this 
stress, accompanied by high maternal adrenal androgen concen-
trations, is a risk factor for autism. (14) The studies examined in 
this review did not specifically measure the psychosocial stress 
and testosterone concentrations in migrants. However, this could 
be investigated and in order to do so the prenatal testosterone 
exposure should be estimated by measuring and analyzing the 
finger length ratio. A lower finger length ratio is associated with 
exposure to higher levels of androgens during the second trimester 
and a higher sensitivity for testosterone (15), which offers 
the opportunity for retrospective investigation of these levels. 
Children diagnosed with autism had lower finger length ratios 
than children without the diagnosis (16). The finger length ratio 
was not measured in any of the studies included in this syste-
matic review. Therefore, no conclusions could be made about 
this explanation, based on our research.
Strengths and limitations
One of the strengths of this systematic review is the inclusion 
of all available studies published in the English language over 
the past fifteen years. Only articles from the pubmed/MEDLINE 
database were used for this review which implies that some other 
studies could have been missed. The limitations of the reviewed
studies define most of the limitations of our study. The 
investigation of Lauritsen et al. is not prone to recall bias 
because the diagnoses were made independently for this study 
by clinicians. Another strength of this study is that the risks were 
adjusted for confounders such as age, gender, time of diagnosis 
of the disorder, parental age and place of birth, except for the 
confounder socioeconomic status. In contrast, the outcomes 
in the study of Keen et al. were not adjusted for a number of 
variables known to be risk factors for autism. These confounders 
could potentially have differed between the groups of interest 
in the study. The risk of misclassification of the diagnosis of 
childhood autism in the Danish Psychiatric Central Register is 
believed to be very low, the possibility that some individuals 
with autism were missed cannot be excluded. In most studies 
misclassification is known to be a problem. It is more likely 
to occur if a child has a different cultural background than the 
clinician. In most studies it was unknown if the parent immigrated 
as a child or as an adult. Also, the reason for immigration is 
unknown in most studies. It could be possible that the age of the 
parent at the moment of migration and the reason for leaving 
the country of origin could affect the autism risk.
 Another important limitation of some of the reviewed 
studies was not taking all variables into account that could 
influence the results. Not all of the studies examined risk factors 
for autism such as prenatal exposure to alcohol, smoking and 
drugs. 
Implications and future research
One of the implications of these findings could be screening 
of children born to immigrant mothers. Physicians should be 
aware of the higher risk of autism in these children and consi-
der a screening test in case they notice any atypical behavior. A 
routine screening test could be another option in order to 
diagnose patients as soon as possible.
 The impact of the six major factors Gardener et al.(4) 
mentions needs further investigation.However, maternal 
migrations is one of the most robust and well-studied of 
them. (17) Future research on the importance of this and other 
perinatal factors is recommended in order to identify risk 
groups. Studies of the etiology of autism are crucial in order to 
understandtheunderlying pathophysiology as the cause of au-
tism remains unclear.
Conclusions
Children with autistic disorder typically have more social, 
communication and cognitive delays than children with other 
autism-spectrum disorders(18). Therefore it is crucial to identify 
children with autism as soon as possible. This will have a lot of
benefits such as earlier access to intervention programs and 
an early diagnosis. Also the parents will feel relieved when a 
diagnosis is made, as it gives them a better understanding of 
their child’s behavior (18). There is strong evidence that the 
causes of autism are multifactorial: genetic and environmental. 
(14) We studied one of these factors: the association between 
immigration of the mother and a higher risk of having a child 
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with autism. In this review we described the increased risk for 
immigrated mothers on having a child with autism. Even though 
this is concluded, more research is required to define to what 
extent immigration causes autism, since it is clear that the 
disease is multifactorial.
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introduction 
Living kidney donation has taken place in the Netherlands 
since 1966 and has increased compared with post-mortem 
donation [1]. There are different types of donors: donations after 
brain death and donations after circulatory death, better known 
as heart beating and non-heart beating donors, and living organ 
donation. The numbers of living kidney donations is increasing 
and there is a stabilization in the numbers of organs from 
deceased donors. 18,712 kidney donations have taken place in 
Europe in 2011, of these donations were 20.6% (0-61%) living 
kidney donations [2,3]. In the Netherlands, the number of living 
kidney donations was 26,3 % [2]. Living donation has a major 
impact on the life of the donor, physically, psychologically and 
financially [1,4,5] and often gives a better outcome/prognosis 
for the receiver compared with post-mortem donation [5,6]. 
Should living donors be compensated for their kidney?
Question
A person can donate a kidney with anonymous, altruistic 
intentions, known as the Samaritan donors or because they 
know someone who needs a new kidney. When a person 
decides to donate a kidney, they go through the living 
donation process. This consists of screening, surgery and the 
postoperative period [1]. The donor is confronted with both 
physical and psychological challenges associated with the 
operation, the risks it entails, and the long-term risks of living 
with one kidney. They also face the financial burden of medical 
expenses and will be temporarily in the Health Insurance Act. 
In the Netherlands, the medical costs that are incurred by the 
donor are reimbursed by health insurance and they are entitled 
to a benefit of the Health Insurance Act, which is provided by 
the Netherlands Employees Insurance, the “UWV”. In addition, 
they are eligible for an allowance, which was introduced in 
January 1, 2011 by the Dutch Transplant Foundation [1]. 
Therefore the direct expenses of the donation should be cover-
ed for the donor. The Center for Ethics and Health (CEG) has 
suggested an additional financial stimulation, for example in 
the form of a lifetime exemption of health insurance premiums 
[7]. Through this stimulus the Centre for Ethics and Health 
expects more people would be willing to donate a kidney [7]. 
However, the Netherlands has a prohibition on the provision of 
financial compensations for donation [8]. 
The question is whether this is reasonable for the donor. Donors 
help a patient with chronic kidney failure, but are then exposed 
to the risks of the surgery and will have to continue living with 
one kidney. Should kidney donors receive compensation in ex-
change for their kidney donation?
Medical situation
Living donation brings risks for the donor during and after the 
surgery. Of these living donations, the risk of death during and 
immediately following surgery is the greatest. However, this 
risk is minimal [9-11]. In the short term there is a small risk 
of spleen injury, thrombosis, wound infection, bleeding and 
pneumonia [9,10]. It is hypothesized that long term effects are 
seen with declining kidney function, but the available research 
is inconclusive [9-11]. Some of the latest studies show that kid-
ney donors have an increased long-term risk for end-stage renal 
disease (ESRD) compared with people who did not donated a 
kidney [12]. Studies have shown there is a minimal increased 
risk of hypertension and proteinuria [9,10]. Also, female donors 
have an increased risk of developing preeclampsia during preg-
nancy, compared with women who have not donated a kidney 
[9,11]. In addition to the physical issues, living donation could 
psychologically affect the donor as well [9,13].
Ethical situation  
Beside the financial and medical aspects, living donation also 
involves ethical aspects. The surgeon must consider whether 
the improved health of the recipient can be seen as a greater 
benefit compared to the attendant risks faced by the donor [14]. 
Another ethical issue is autonomy. An individual in the 
Netherlands may, free of pressure and coercion from others, 
voluntarily register as a living kidney donor based on his or 
her own values. Similarly, the individual has the opportunity to 
withdraw at any time as a donor [1]. A third issue to consider is 
that of justice. Equals should be treated as equals and unequals 
as unequals according to Rawls’ principle of justice [15]. 
Therefore all people should be treated equally, also in terms of 
access to health care. Factors such as gender, social status or 
race, should not be considered when it comes to organ donation.
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argumentation
A compensation for living donation can be viewed in different 
ways. The compensation can be viewed as a payment for goods, 
which is a donated kidney in this case. It could be seen as a 
compensation for the lost time and the costs incurred, and it 
could be seen as a gift which stands for appreciation [16]. 
Paying non-medical expenses associated with the transplant is 
a possibility of paying off debt, an option which is preferred in 
the study of Gordon et al. [17] which investigated the change of 
willingness to donate in case of a financial compensation [17]. 
The Dutch government prohibits any form of compensation 
that is a direct consequence of the removal of an organ [8]. As 
long as there is no solution to the growing waiting lists and the 
associated cost from morbidity and mortality, a compensation 
for ethical living donation should be considered to increase the 
numbers of living donations!
In my opinion there should be further compensation for living 
donation, in addition to the compensation which already exists 
in the Netherlands. This compensation should be provided 
because of the risks to which the donor is exposed. The donor 
indirectly promotes the welfare of the recipient and acts using 
the principle of beneficence. The principle of beneficence 
should in my view be the reason for remuneration and not the 
delivered organ itself. However this distinction may not be 
allowed under current European law. [8] 
It is expected that with the introduction of a compensation 
system the numbers of (anonymous) donations will increase 
and the waiting period will decrease. Ethical screening would 
be required as the autonomy of a donor may be compromised 
when an individual is financially uncertain. 
The form of the compensation could vary. Donors could opt for 
an one-time payment for their organs, they could opt for a small 
life time benefit either as cash or an indirect benefit such as 
lifetime discount on the premium. The indirect compensation is 
the best option as it ensures the donor is not rewarded directly 
or temporarily. Therefore the autonomy of the donor is less at 
risk. 
The principle of justice, which stands for division and equality, 
would be jeopardized if the compensation for living donation 
should be paid by the receiver himself. This would have the 
effect that only the wealthy could afford a kidney transplant. To 
prevent this, it should be paid by a multidisciplinary authority 
like the Dutch Transplant Foundation [7,18]. The costs of a 
kidney transplant are lower than the costs incurred annually 
by the chronic kidney patients on hemodialysis and peritoneal 
dialysis [19]. Therefore these funds could be redirected toward 
reimbursement of donors’ annual insurance premium. 
There is little evidence that shows the number of (anonymous) 
donations will actually increase after the introduction of a 
compensation. One of the reasons is that organ compensation 
is prohibited in many countries [8,14]. Only in Iran such a 
reimbursement is permitted. In 2006, there was no waiting list 
in Iran for kidney donation [14,20]. The data from the Iranian 
model do not provide sufficient evidence that compensation for 
living donation in the Netherlands will help shorten the waiting 
list. Further research is necessary [14].
Conclusion
A compensation available to living kidney donors should 
certainly be considered in the Netherlands mainly, because it is 
expected that the number of (anonymous) donors will increase. 
This could be verified through a pilot project, where a compen-
sation is offered temporarily during the duration of the pilot. 
The introduction of compensation does not cause a conflict 
with the ethical principles. Individuals remain free to choose to 
register as donors, whether they will receive compensation or 
not. By choosing an indirect compensation, such as a discount 
on the premium for health insurance, the principle of justice 
will be prevented from being jeopardized. This can also be 
prevented by making the financial compensation paid by a 
multidisciplinary authority, so rich and poor have equal chance 
of receiving a new kidney.
Also, the medical costs, which are made in the current situation 
due to chronic kidney patients, can be reduced by an increase 
in the number of kidney transplants as a result of the increased 
number of donor kidneys. This could offset the costs of a 
compensation system.
Thus compensation for living donors of kidneys should be 
considered.
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abstract
Deviations in body composition (subcutaneous fat, visceral 
fat, and skeletal muscle), that can occur independently of body 
mass index (BMI), are considered risk factors for impaired 
outcome in patients with various benign and malignant diseases. 
In recent years, new techniques have been developed to 
accurately measure body composition. One of these methods 
uses single-slice computed tomography (CT)-scans to measure 
both skeletal muscle and adipose tissue. It has been shown that 
this method correlates with the total body muscle and fat mass. 
Determining low skeletal muscle mass using CT-scans during 
oncological workup could provide options for interventions 
to optimize the physical condition, for example in patients 
scheduled for oncological resection. 
introduction
 The body mass index (BMI) is widely used in population 
based studies and to categorize individual’s weight. The BMI is 
an attractive measure, as it is an easily obtainable, cheap, and 
non-invasive tool for assessing excess body fat. However, its 
weakness lies herein. BMI is a proxy measure and does not take 
distinct body composition elements into account (e.g. skeletal 
muscle tissue or adipose tissue). This may be one reason that 
BMI fails to accurately predict postoperative outcome(1).
 In recent years, body composition (i.e. subcutaneous 
adipose tissue, visceral adipose tissue and skeletal muscle tissue) 
has extensively been studied as predictor for outcome following 
for example oncological treatment(2), transplant surgery(3, 4), 
emergency surgery(5), intensive care unit (ICU) admission(6), 
trauma(7), and vascular surgery(8). Deviations in these 
components, which can also occur within a normal weight 
range or BMI, are associated with individual risk and 
reduced survival in patients with various benign and malignant 
diseases(9). Visceral adipose tissue differs from subcutaneous 
adipose tissue in that it is more metabolically active(9, 10). A 
high proportion of visceral adipose tissue is related to a chronic 
inflammatory state and the metabolic syndrome(11). 
Depletion of skeletal muscle mass and reduction of muscle function, 
which is called sarcopenia (from the Greek sarx [i.e. flesh] 
and penia [i.e. lack of]), is a phenomenon that occurs indepen-
dently of BMI. Sarcopenia was first described in geriatric patient 
populations(12) and is related to frailty (i.e. a status leading to an 
impaired reaction to stressors) and functional impairment in the 
elderly(13). The distribution of different tissue compartments can 
be misbalanced. Patients with sarcopenic obesity, for example, 
have both risk factors of low muscle mass and a high BMI, resulting 
from a high proportion of adipose tissue(14). Consequently, 
sarcopenia can be an occult phenomenon. This emphasizes 
the importance of body composition measuring techniques 
compared with BMI (15, 16).
 Computed tomography (CT) and magnetic resonance 
imaging (MRI) are known for their specificity and precision 
regarding body imaging. In recent years, it has come to ligh 
that it is possible to accurately measure body composition 
using these techniques. Parameters resulting from these 
measurements have extensively been validated and applied(16). 
Prado et al. were the first to investigate the association between 
CT-assessed skeletal muscle mass and outcome in oncological 
patients in 2008(2) and hereby introduced the term sarcopenia 
in oncology.
 In this article we will discuss some of the novel 
findings in this area of research, with emphasis on oncological 
populations.
 
Measuring body composition
 A suitable, precise method which is applicable on a large 
scale and with high specificity was wanted to perform body 
composition analyses. Between 1979 and 1981, Heymsfield et al. 
reported the use of CT to measure skeletal muscle and visceral 
adipose tissue mass(17). In 1986, Kvist et al. were the first to 
assess whole-body adipose tissue volumes with CT, using just 
several slices(18). A standardized part of the body with images at 
specific skeletal landmarks were chosen(16). 
Erasmus Journal of Medicine • vol 5 - no 1 - October 201552
Shen et al. showed high correlations between two dimensional 
abdominal skeletal muscle and adipose tissue areas measured 
on just a single slice and their respective three dimensional total 
body volumes, after examination in a large sample of diverse 
subjects in 2004(19). In most studies that have later been 
performed the third lumbar vertebra (L3) was usually chosen as 
the level to perform these measurements. Prado et al. showed that 
measurements performed at the level of L3 were related to impaired 
outcomes in malignancies of the upper respiratory and digestive 
tract in 2008 (2). This CT-based method was also shown to 
provide more detail than the formerly used dual X-ray 
absorptiometry (DXA) and bioelectrical impedance analysis 
(BIA)(15).
 In most oncological and surgical populations a CT-scan is 
routinely made as part of the diagnostic tract, preoperative 
work-up or tumor down staging. The total body is rarely depicted 
in this setting, which is why the cross sectional area at the L3 level, 
which correlates well with the total muscle mass(19, 20) proves 
its use. The measurements at the L3 level are performed on a 
CT-slice on which both the processi transversi of the lumbar 
vertebra are visible(16). At this level all the muscles visible 
(rectus abdominis, obliquus internus abdominis, obliquus externus 
abdominis, transversus abdominis, psoas major, quadratus 
lumborum and the erector spinae muscles) are selected using a 
software package. Pre-defined radio density ranges for 
muscle are used to discriminate between muscle and fat. 
(Figure 1). There are various software programs to perform 
these measurements, based on the same principle. One of these 
programs is MeVisLab FatSeg, an Erasmus MC developed 
program. Predefined ranges for muscle tissue of -30 to 150 
Hounsfield units (HU) are used. Hounsfield units are the 
standard unit for radio density. Air is predefined as being very 
radiolucent with a radio density of -1000 HU, whereas pure 
water is 0 HU and metals appear very radio dense with +1000 
HU. Since intra-abdominal organs have the same range of radio 
density as muscle, the approximate area of the muscles must be 
manually selected. These measurements result in the 
cross-sectional muscle area. This area is adjusted for height, 
which results in the L3-muscle index (cm2/m2). The pro-
gram also automatically calculates the average HU of 
 the selected tissue area. Generally, adipose tissue is 
measured in the same way, in that the approximate area 
must be manually selected. (Figure 2) Subcutaneous adipose 
tissue is the adipose tissue between the skin and the outer core 
muscle fascia. Visceral adipose tissue is the adipose tissue within 
the musculature of the abdomen, surrounding the abdominal 
organs. The range of radio density is set between -190 HU and 
-30 HU. The average HU is also calculated automatically for 
this area. Some parts of the internal organs are also selected 
using these ranges, such as intestinal contents. These areas must 
be manually removed. The visceral area is usually not corrected 
for height, since the a person’s height does not correlate with 
the amount of visceral fat, unlike muscle mass. 
CT-based cross-sectional skeletal muscle measurements are an 
easily obtainable method showing a limited inter-observer 
variability(21). In spite of the CT-scan being specific and precise, 
it is not recommended as a standard method to determine body 
composition in all populations. Besides the added expenses and 
effort, patients are exposed to additional radiation(22). However, as 
the CT-scan is routinely used in routine surgical oncology practice, 
this method does not raise additional costs and does not entail 
additional patient radiation exposure. Therefore, it is currently 
recommended for research purposes(23), and it seems a method 
ready for use. 
 Currently, there is still much debate regarding adequate 
cut-off values to categorize patients as sarcopenic or 
non-sarcopenic. No international consensus has been reached 
yet. Prado et al. used cut-off values based on risk stratificati-
on(2). These have since commonly been used, but some studies 
use other cut-off values(24-26). One could wonder whether one 
set of cut-off values is applicable for various patient popula-
tions. Therefore, gender-, age-, ethnicity- and disease specific 
cut-off values may be needed.
 
Clinical relevance
 In malignant disease, sarcopenia has been shown a poor 
prognostic factor in various malignancies, such as hepatocellular 
carcinoma (27, 28), melanoma (29) and pancreatic cancer (30). 
It has also been proven that sarcopenia negatively influences 
post-operative outcome following oncologic resection in 
various malignancies, such as pancreatic, hepatic and colorectal 
cancer(31-33).
Clinical Image
Skeletal muscle colored dark blue on the level of the third lumbar vertebra (L3). 
On the left: a female sarcopenic patient (according to the cut-off values of Prado 
et al.(2)) of 90 years. This patient had a BMI of 27 kg/m2, cross-sectional skeletal 
muscle area of 75 cm2 and a height of 1.64 m which resulted in a L3-index of 
28 cm2/m2. The average radio density was 15 HU. On the right: a male non-
sarcopenic patient (according to the same cut-off values) of 41 years, a BMI of 30 
kg/m2, cross-sectional skeletal muscle area of 241 cm2 and a height of 1.70 m 
resulting in a L3-index of 83 cm2/m2. The average radio density was 28 HU.
Visceral adipose tissue colored dark blue on the level of the third lumbar vertebra 
level (L3). On the left: a female patient of 36 years with a BMI of 21 kg/m2 and 
visceral adipose tissue area of 26 cm2. On the right: a male patient of 48 years 
with a  BMI of 24 kg/m2 and visceral adipose tissue area of 323 cm2. Unlike for 
muscle mass, adipose tissue is not related to a person’s height. Therefore, the 
acquired area is not corrected for height.
Figure 1 
Figure 2 
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 In patients undergoing surgery for colorectal cancer, 
sarcopenia is associated with a higher risk of complications and 
worsened postoperative course: the infection risk is almost double 
in sarcopenic patients compared with non-sarcopenic patients. 
Furthermore,  length of hospital stay (LOS) was significantly 
longer (33), in-hospital and thirty-day mortality rates were 
significantly higher (21), and five-year recurrence free- and 
overall survival were significantly shorter in sarcopenic 
patients (34).
 Loss of skeletal muscle mass also negatively impacts the 
outcome in patients undergoing resection of colorectal liver 
metastases (24), and is independently associated with an increased 
risk of chemotherapy toxicity among metastatic colorectal 
patients (35). A poorer prognosis in sarcopenic is reported in patients 
undergoing adjuvant chemotherapy after colorectal cancer 
surgery as well(36). 
 Besides sarcopenia, a low skeletal muscle radio density, 
reflecting a high amount of intramuscular adipose tissue, has 
been identified as an independent poor prognostic factor (26, 37). 
In similar colorectal surgical populations, visceral obesity leads 
to a longer LOS, a higher postoperative morbidity rate and 
longer operative time(11).
 However, all afore mentioned findings are based on 
retrospective cohort studies, Therefore, the level of evidence 
remains weak up to now. Nevertheless, a recent prospective stu-
dy among clorectal cancer patients confirmed that sarcopenia is 
a predictor for postoperative complications(38).
 Sarcopenia assessment during routine oncological 
pre-operative workup could provide options for unfit patients 
to pursue a better physical state before surgery. The interval 
between the CT-scan and operation could for instance be used 
to offer nutritional support, physical exercise therapy and 
treatment of other anorexia causes, such as pain(39, 40).
 
Summary
 Determination of BMI is deemed inaccurate in some 
settings, since it does not take into account distinct body 
composition compartments, which may also occur in people within 
the normal weight range. Multiple methods have been developed to 
assess body composition. An emerging method is skeletal muscle 
or visceral or subcutaneous adipose tissue measurement on a 
single slice CT-scan. Low skeletal muscle mass and high visceral 
adipose tissue mass have been identified as predictors for impaired 
outcome in various (surgical) oncological populations. Assessment of 
sarcopenia during oncological workup could provide options 
for intervention to optimize the physical condition and improve 
outcome in patients scheduled for oncological resection. 
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Instructions for EJM authors
For the convenience of our future contributors and 
our readers, we publish here the advice we give to 
our reviewers.
In the process of reviewing a paper, please refer to the  
following points:
•  Your first step should be to evaluate your relationship  
with the authors. To ensure the credibility of the process, 
reviewers should not have a conflict of interest with the  
authors. If this is a case, the paper should be appointed to 
other reviewers. Please keep us informed whether conflict  
of interest is an issue for you as an appointed reviewer.
• Is this work relevant and interesting for EJM? 
• Are the objectives appropriate and clearly stated?
• Are the data valid?
• Are the conclusions valid and properly supported?
• Is the already existing work described adequately?
• Paper structure/organization; is this logical?
• Does abstract clearly convey meaning of the paper?
•  Is the paper well written and can be easily understood? 
(Please keep in mind that students don’t have the experience 
to reed throughout the paper very quickly and to understand 
everything in a research paper at the first glance)
• Are all sections really needed, or could they be shortened?
•  Is the science reliable? Please, be aware of ethical issues 
such as plagiarism!
 Comments should be detailed and specific. Mentoring the 
authors includes helping authors improve their paper under 
review even if these papers will/could not be accepted for 
publication in our journal. By careful reviewing, you will help 
improving the quality of papers published elsewhere too. Avoid 
vague complaints and provide appropriate citations if authors 
are unaware of the relevant work. 
 Please consider a manuscript received for reviewing as a  
confidential document and do not discuss the content of this 
paper with others. To maintain the validity of this process, you 
should never contact the authors about the paper under review. 
 The review process serves two important goals: providing 
guidance to the authors to improve the quality of their paper,  
and providing the editor or editorial board with valuable  
recommendations regarding the acceptance or rejection of the  
peer-reviewed papers (along the whole spectrum of major  
revision- minor revision- rejection). So it is important that you 
give comments to the authors, and to the editor in separate 
sections. Please use the provided form, because this makes life 
easier for you, the editor and the authors.
 EJM is committed to rapid editorial decisions and  
publication. We request that reviewers return their comments 
within the time indicated at invitation. If any unanticipated  
difficulties arise that may prevent you from submitting the 
review on time, contact us by sending an email to the editorial 
office at ejm@erasmusmc.nl. You are welcome to contact us if 
you have any questions. 
 For more information about guidelines for the review 
process, please visit our website: www.erasmusmc.nl/ejm.  
We also recommend you to view the presentations of the EJM  
workshop on our website. Here you can find instructions about 
how to scan through a paper and grab its essence, and how to 
structure your comments to the authors and to the editor. 
July 2014, Editorial board of Erasmus Journal of Medicine.
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Instructions for EJM authors
General
The instructions that follow have several purposes. First, we 
want to make life easy for you, the authors, and for the editors 
and peer reviewers, the layout (prepress) people, and the  
journal readers.
 The section Authors instructions storyline, on the website 
(www.erasmusmc.nl/erasmusjournalofmedicine) will help you 
to organize your article in a logical, credible and readable way. 
This will help you - it tells you what goes where—and, thus, 
save you time. It will help the editors and peer  
reviewers—they will easily see the credibility and relevance 
of your work— and, thus, save them from writing rejection 
letters. And, it will help readers to quickly and easily read and 
understand your work and see its value.
 The section entitled Formatting Instructions will help 
you as well; the basic idea is to keep the formatting as simple 
as possible, so you can focus on content and not get involved 
with layout. The language editor and the prepress people will 
also be able to more efficiently do their jobs. Please follow 
these instructions. 
Please be aware that we will have to return papers that do not 
conform to these instructions to the authors.
What you can enter
Research news - Research articles describe one study or 
analysis, usually from an elective research project or one 
of the masters programs. Number of words: max. 3500 + 4 
figures or tables.
Extended abstracts - Extended abstracts consist of a 
condensed presentation of final or preliminary results of a 
study. Extended abstracts can concern ongoing research that 
is not yet published elsewhere which is comparable with a 
congress presentation thus does not require copyright transfer. 
An extended abstract can also be submitted after publication in 
another Journal if possible with extra figures, this does require 
proper referencing. Number of words: 350 words + 1 figure or 
table. 
Research papers - Here researchers or teachers describe 
ongoing research projects at the Erasmus Medical centre for 
which they want to invite students to participate. Number of 
words: 350. 
Systematic reviews - A systematic review is a literature 
review focused on a research question that tries to identify,  
appraise, select and synthesize all high quality research  
evidence relevant to that question in a quantitative way.  
Systematic reviews of high-quality randomized controlled 
trials are crucial to evidence-based medicine, and are  
considered very important by the editorial board of EJM. 
Besides health interventions, systematic reviews may concern 
clinical tests, public health interventions, social interventions, 
adverse effects, and economic evaluations. Number of words: 
3000 + 3 figures or tables. 
Opinion papers - These are papers that reflect the opinion 
of the author on a scientific topic. The author should be clear 
where evidence ends and personal opinion starts. A paper 
typically has a length of about 1000 words.
Clinical lesson/question - A clinical lesson should present 
a scenario and a concrete related question about a disease or 
condition, the article should elaborate on possible approaches 
or treatment options for this disease or condition. Conclusion 
should provice a solid evidence based conclusion on the  
preferred approach or treatment. Number of words: 1000 + 1 
figure or table. 
Case reports - A case report consists of the initial  
presentation, medical history, examination, tests performed, 
eventual outcome and discussion on the case backed up by 
scientific literature. Number of words: 900 + 1 figure or table. 
Clinical quiz - A clinical quiz should present a scenario and 
a concrete related question about the disease or condition, 
preferably accompanied by a clinical image, and four plausible 
treatment options or courses of action. Conclusion should 
elaborate on which is the correct option and why. Number of 
words: 600 + 1 figure or table. 
Clinical images - Clinical images should present a typical  
abnormality on a photograph/imaging tests of a patient or on 
an additional investigation. It must be accompanied by an  
elaboration on the clinical diagnosis. Number of words: 350 
+ 1 figure. Make sure that the patient is not identifiable or 
that the data presented traceable to the patient. Additionally, 
written consent should be obtained from presented patient. 
We expect the author to refer to scientific literature to back up 
their case presentations.
Comments - In this section editors, or faculty staff, as well 
students are invited to write a short critical comment on a 
paper, putting it into perspective for a broader medical public 
readership. Number of words: 350.
Letters to the editor - The editorial board encourages 
students to write a letter to the editor to comment on published 
papers, or on the journal in general. These will be published 
on the website of the journal. Letters should not exceed 200 
words and may be abbreviated by the editor. 
the review process
Papers may be submitted to the editorial office. Please indicate 
which author will act as corresponding author. We expect this 
author to maintain contact with the other authors and to speak 
and decide on their behalf.
 Each paper will be assigned to a team consisting of a  
managing editor and an associate editor. Each submitted paper  
will be checked for compliance with the author instructions. If 
this is not the case, the paper may be returned to the author. 
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Instructions for EJM authors
 When the paper is taken into review, it will be sent out 
to two external reviewers, a student and a staff member of 
Erasmus MC. Based upon these reviewers comments, their 
recommendations and the opinion of the editorial team, a 
decision will be made: reject, major revision, minor revision, 
accept with or without minor changes.
 The paper will then be returned to the corresponding  
author, along with the recommendation. We try to return 
papers within 3 weeks after submission. When a paper is 
rejected, it cannot be resubmitted, but we encourage  
resubmissions when we recommend major or minor changes 
to a paper. Resubmitted paper will be reviewed again by the 
same reviewers and editorial team.
 Before a paper can be accepted for publication, we will 
need a statement that the staff member that supervised your 
work agrees with the submission of your paper. Moreover, 
we need a signed Copyright Transfer Agreement (CTA) and 
a signed Conflict of Interest statement. When your research 
project involves patients or volunteers, we need a statement 
in the paper that the research protocol has been reviewed by a 
Medical Ethics Committee. Failure to provide this information 
at an early stage of the submission may impair the review 
process. 
 When a paper is accepted for publication, it will often  
be forwarded to our language editing and restructuring  
editors. They will each in turn give recommendations and ask 
the author adapt the paper accordingly. When this phase is 
completed, the paper will be forwarded to the publisher.  
Page proofs will be sent to the author for a final check.
Formatting instructions
Entry format - Papers should be submitted by email, to
ejm@erasmusmc.nl. Word 2007 files are preferred for the  
initial submission. The file should include all figures and 
tables. 
Title page - The title page should clearly identify the 
authors, the institute where the research project was carried 
out, as well as the staff member who supervised the project. 
The corresponding author name (first name and family name), 
email address, student id, should be clearly indicated. In case 
of multiple authors, state functions and departments only in 
superscript in alphabetical order.
Example:
First name A.G. Family namea and First name W.F. Family 
namea Supervisor: First name R. Lastnameb
a  Medical students, Erasmus MC University Medical Center  
Rotterdam, the Netherlands
b  Dept. of Internal Medicine, Erasmus MC University Medical 
Center Rotterdam, the Netherlands
Correspondence: First name A.G. Family name,  
email: FirstnameFamilyname@me.com.
Structure - Please use the following sections in all papers 
(except in comments and opinion papers): Abstract,  
Introduction, Methods, Results, Discussion, References, 
Tables, Figures.
References - Number references in order of appearance.
References should have the following format:
Rothwell, P. M. Medical and surgical management of  
symptomatic carotid stenosis. Int J Stroke. 2006; 1: 140-149. 
(I.e. year;vol:ppp-ppp) In case of more than 3 authors, name 
the first 3 and insert “et al.”. Limit the number of references 
to 30. References should appear in the text as follows: “… 
treatment is of proven benefit.[1]”
Tables and figures - Tables and illustrations (both  
numbered in Arabic numerals) should be prepared on separate 
pages. Number tables and figures separately and consecutively. 
Tables require a heading and figures a legend, also prepared 
on a separate page and should be formatted with a text editor 
(example). Figures should be submitted electronically. B/w 
half-tone and color illustrations must have a final resolution of 
300 dpi after scaling, line drawings one of 800-1,200 dpi (jpg 
and tiff is an acceptable format). Please note that all  
color-figures will be converted to gray tones. Please adapt 
graphs to suit this format, i.e. make use of dotted and dashed 
lines and hatched bars instead of colored items.. The final 
submission should contain figures as JPG or TIFF files.
Page layout
• Standard margins
• no headers or footers
• no columns
• left align (ragged right)
• font: 12pt Arial
• single line spacing
• main headings 14 pt bold; subheading 12 point italic
•  indent every paragraph, except after headings, tables, bul-
leted lists or figures
Other formatting
•  number all tables and figures sequentially
•  place tables and figures at the end of article; insert captions 
at correct locations in body text
• no text boxes
• no footnotes or end notes
•  do not submit figures with text as drawing objects (they  
cannot be edited)
•  limit the use of italics and do not use italics for simple 
emphasis; do not italicize quotations; quotation marks are 
sufficient
•  do not use italics for commonly understood Latin  
expressions such as “in vitro”
•  use italics for other foreign words, such as expressions in 
Dutch
• no “sub-paragraphs” 
• no hyphenation (afbreking)
Language
US English spelling and punctuation
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introduction
1.  What is the health-related problem that your  
research helps to solve?
2. What is your strategy to solve the problem?
3. What is your research question/hypothesis?
  Whether a question or a hypothesis, state it in terms of  
2 items:
 •  variables: the measurable/observable independent and 
outcome variables that you measured/observed and 
  •  relationships: the relationships between those variables 
that your data analyses were designed to determine.
4.  The core concept of the methods you used to answer the 
research question
  Briefly describe the core concept of the methods at the  
end of the Introduction section. This helps readers to 
understand the complex details that are then presented in 
the Methods section
Methods section 
Organize the details of the Methods section under subheadings.
Possible subheadings:
What was studied and study design (subheading)
Describe the details of 
−  what was studied: sample from a patient/animal  
population, and 
−  the design of the study: case-series, cohort study,  
case-control study, randomized trial, etc.
Data collection (subheading)
Describe the details of how the data was collected/observed
 Note
  Observable variables will be credible only if qualified 
observers and validated instruments were used to assess 
them. Examples of observable variables include patient 
symptoms, subject responses to open interviews/ 
questionnaires, ultrasound/MRI/CT images, assessments 
of articles in a literature review etc. In such cases, build 
credibility in the Methods section; report “who” observed 
and interpreted the data. For example, “An experienced 
radiologist interpreted the images.”
 Note 
  When reporting on decisions/judgments that were made, 
use the “we” form—take responsibility for what you did. 
 Note 
  The Methods section reports historical facts and must be in 
past tense. 
Data analysis (subheading)
results section
5. The core concept of the Results
  Briefly describe the core concept of the results in a short 
paragraph at the beginning of the Results section. This 
helps readers to understand the details that follow. Note 
just as in the Methods section, this section reports  
historical facts and must be in past tense.
Then organize the details of your Results under sub-headings, 
for example:
Patient/animal characteristics 
Data 
Statistical results 
discussion section
Structure your Discussion to focus on 4 core concepts  
(6, 7, 8, and 9 below).
6. The answer to your research question 
   Present this right at the top of the Discussion section—the 
very first sentence,  a present tense statement that  
expresses—to the best of your knowledge—how the world 
works as related to your research question/hypothesis. It 
is a direct answer to the question/hypothesis stated in the 
Introduction. 
7. Support that answer?
 a)  how your factual findings, (expressed in past tense), 
support your answer. 
 b) relating the findings of others to your answer.  
 c)  theoretical considerations that support your  
answer. 
Limitations (subheading)
8. The limitations to that answer 
  Focus explicitly on limitations related to possible confoun-
ders:  
 • sample size
 • specific locations/medical centers of your study, 
 • possible ethnic/cultural variables, 
 • uncontrolled patient/subject characteristics and 
 • underlying assumptions.
Conclusions (subheading) 
The Conclusion is not a summary, but should focus on the 
consequences of your work. Structure this subsection using 
separate paragraphs that state 2 main messages (9 and 10)
9.  What are the practical/theoretical consequences of your 
answer?
  The value—relevance— of your work: how it helps to 
solve the problem described at the beginning of the  
Introduction. 
10.  What is a next step to help solve the original problem?
 • a new research question to be answered 
 •  a refinement of the present study to reduce limitations 
 • a protocol to implement the findings in the clinic 
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